JP6290412B2 - イミダゾロン系誘導体、その医薬組成物及び用途 - Google Patents
イミダゾロン系誘導体、その医薬組成物及び用途 Download PDFInfo
- Publication number
- JP6290412B2 JP6290412B2 JP2016533613A JP2016533613A JP6290412B2 JP 6290412 B2 JP6290412 B2 JP 6290412B2 JP 2016533613 A JP2016533613 A JP 2016533613A JP 2016533613 A JP2016533613 A JP 2016533613A JP 6290412 B2 JP6290412 B2 JP 6290412B2
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- imidazo
- quinolin
- mmol
- pyridin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 11
- WZELXJBMMZFDDU-UHFFFAOYSA-N Imidazol-2-one Chemical class O=C1N=CC=N1 WZELXJBMMZFDDU-UHFFFAOYSA-N 0.000 title description 3
- 150000001875 compounds Chemical class 0.000 claims description 160
- -1 6- (1-methyl-1H-pyrazol-4-yl) pyridin-3-yl Chemical group 0.000 claims description 120
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 claims description 40
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 claims description 40
- 201000010099 disease Diseases 0.000 claims description 38
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 38
- 150000003839 salts Chemical class 0.000 claims description 28
- 239000000126 substance Substances 0.000 claims description 28
- CFPBYGKISUKURJ-UHFFFAOYSA-N 3h-quinolin-2-one Chemical compound C1=CC=CC2=NC(=O)CC=C21 CFPBYGKISUKURJ-UHFFFAOYSA-N 0.000 claims description 27
- 206010028980 Neoplasm Diseases 0.000 claims description 15
- 108091007960 PI3Ks Proteins 0.000 claims description 15
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 15
- 238000001948 isotopic labelling Methods 0.000 claims description 14
- 239000003814 drug Substances 0.000 claims description 13
- 201000011510 cancer Diseases 0.000 claims description 10
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 10
- 238000004519 manufacturing process Methods 0.000 claims description 9
- 229940079593 drug Drugs 0.000 claims description 8
- VNVSMYNQNASCOA-UHFFFAOYSA-N 3-methyl-8-[6-(1-methylpyrazol-4-yl)pyridin-3-yl]-1-(1-methylsulfonylpiperidin-3-yl)imidazo[4,5-c]quinolin-2-one Chemical compound C1=NN(C)C=C1C1=CC=C(C=2C=C3C=4N(C5CN(CCC5)S(C)(=O)=O)C(=O)N(C)C=4C=NC3=CC=2)C=N1 VNVSMYNQNASCOA-UHFFFAOYSA-N 0.000 claims description 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 6
- 208000030159 metabolic disease Diseases 0.000 claims description 6
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 5
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 5
- 125000004076 pyridyl group Chemical group 0.000 claims description 4
- 150000003852 triazoles Chemical class 0.000 claims description 4
- VKUWAWNKLHNKAP-UHFFFAOYSA-N 1-(1-acetylpyrrolidin-3-yl)-3-methyl-8-[6-(1-methylpyrazol-4-yl)pyridin-3-yl]imidazo[4,5-c]quinolin-2-one Chemical compound C(C)(=O)N1CC(CC1)N1C(N(C=2C=NC=3C=CC(=CC=3C=21)C=1C=NC(=CC=1)C=1C=NN(C=1)C)C)=O VKUWAWNKLHNKAP-UHFFFAOYSA-N 0.000 claims description 3
- ZIEQYBFMPKXGAW-UHFFFAOYSA-N 1-[1-(2-hydroxyacetyl)piperidin-3-yl]-3-methyl-8-[6-(1-methylpyrazol-4-yl)pyridin-3-yl]imidazo[4,5-c]quinolin-2-one Chemical compound OCC(=O)N1CC(CCC1)N1C(N(C=2C=NC=3C=CC(=CC=3C=21)C=1C=NC(=CC=1)C=1C=NN(C=1)C)C)=O ZIEQYBFMPKXGAW-UHFFFAOYSA-N 0.000 claims description 3
- SUUMVCJDZHQGAX-OQHSHRKDSA-N 1-[1-[(2R)-2-hydroxypropanoyl]piperidin-3-yl]-3-methyl-8-[6-(1-methylpyrazol-4-yl)pyridin-3-yl]imidazo[4,5-c]quinolin-2-one Chemical compound O[C@@H](C(=O)N1CC(CCC1)N1C(N(C=2C=NC=3C=CC(=CC=3C=21)C=1C=NC(=CC=1)C=1C=NN(C=1)C)C)=O)C SUUMVCJDZHQGAX-OQHSHRKDSA-N 0.000 claims description 3
- BYXLUFLERDBTHN-GOSISDBHSA-N 3-methyl-1-[(3R)-1-methylsulfonylpiperidin-3-yl]-8-[6-(1-methyltriazol-4-yl)pyridin-3-yl]imidazo[4,5-c]quinolin-2-one Chemical compound CN1C(N(C2=C1C=NC=1C=CC(=CC2=1)C=1C=NC(=CC=1)C=1N=NN(C=1)C)[C@H]1CN(CCC1)S(=O)(=O)C)=O BYXLUFLERDBTHN-GOSISDBHSA-N 0.000 claims description 3
- CYACHPMTYAXDNS-UHFFFAOYSA-N 3-methyl-1-[1-(4-methylphenyl)sulfonylpyrrolidin-3-yl]-8-[6-(1-methylpyrazol-4-yl)pyridin-3-yl]imidazo[4,5-c]quinolin-2-one Chemical compound CN1C(N(C2=C1C=NC=1C=CC(=CC2=1)C=1C=NC(=CC=1)C=1C=NN(C=1)C)C1CN(CC1)S(=O)(=O)C1=CC=C(C=C1)C)=O CYACHPMTYAXDNS-UHFFFAOYSA-N 0.000 claims description 3
- CCOSNMIHAUJMOT-SFHVURJKSA-N 3-methyl-8-[6-(1-methylpyrazol-3-yl)pyridin-3-yl]-1-[(3S)-1-methylsulfonylpyrrolidin-3-yl]imidazo[4,5-c]quinolin-2-one Chemical compound CN1C(N(C2=C1C=NC=1C=CC(=CC2=1)C=1C=NC(=CC=1)C1=NN(C=C1)C)[C@@H]1CN(CC1)S(=O)(=O)C)=O CCOSNMIHAUJMOT-SFHVURJKSA-N 0.000 claims description 3
- MRYXQEWYPNZMLN-UHFFFAOYSA-N 3-methyl-8-[6-(1-methylpyrazol-4-yl)pyridin-3-yl]-1-(1-methylpyrrolidin-3-yl)imidazo[4,5-c]quinolin-2-one Chemical compound CN1C(N(C2=C1C=NC=1C=CC(=CC2=1)C=1C=NC(=CC=1)C=1C=NN(C=1)C)C1CN(CC1)C)=O MRYXQEWYPNZMLN-UHFFFAOYSA-N 0.000 claims description 3
- YHPIVSNTHWBRJK-UHFFFAOYSA-N 3-methyl-8-[6-(1-methylpyrazol-4-yl)pyridin-3-yl]-1-(1-methylsulfonylazetidin-3-yl)imidazo[4,5-c]quinolin-2-one Chemical compound CN1C(N(C2=C1C=NC=1C=CC(=CC2=1)C=1C=NC(=CC=1)C=1C=NN(C=1)C)C1CN(C1)S(=O)(=O)C)=O YHPIVSNTHWBRJK-UHFFFAOYSA-N 0.000 claims description 3
- COMGBTRKZCRMBK-UHFFFAOYSA-N 3-methyl-8-[6-(1-methylpyrazol-4-yl)pyridin-3-yl]-1-(1-methylsulfonylpiperidin-4-yl)imidazo[4,5-c]quinolin-2-one Chemical compound CN1C(N(C2=C1C=NC=1C=CC(=CC2=1)C=1C=NC(=CC=1)C=1C=NN(C=1)C)C1CCN(CC1)S(=O)(=O)C)=O COMGBTRKZCRMBK-UHFFFAOYSA-N 0.000 claims description 3
- DXDMJBHDBWZXBF-UHFFFAOYSA-N 3-methyl-8-[6-(1-methylpyrazol-4-yl)pyridin-3-yl]-1-(1-methylsulfonylpyrrolidin-3-yl)imidazo[4,5-c]quinolin-2-one Chemical compound CN1C(N(C2=C1C=NC=1C=CC(=CC2=1)C=1C=NC(=CC=1)C=1C=NN(C=1)C)C1CN(CC1)S(=O)(=O)C)=O DXDMJBHDBWZXBF-UHFFFAOYSA-N 0.000 claims description 3
- UUGVHOCIIQAXPN-UHFFFAOYSA-N 3-methyl-8-[6-(1-methylpyrazol-4-yl)pyridin-3-yl]-1-[1-(2,2,2-trifluoroacetyl)pyrrolidin-3-yl]imidazo[4,5-c]quinolin-2-one Chemical compound CN1C(N(C2=C1C=NC=1C=CC(=CC2=1)C=1C=NC(=CC=1)C=1C=NN(C=1)C)C1CN(CC1)C(C(F)(F)F)=O)=O UUGVHOCIIQAXPN-UHFFFAOYSA-N 0.000 claims description 3
- LYFAZDMTFHLILE-UHFFFAOYSA-N N-[4-[3-methyl-8-[6-(1-methylpyrazol-4-yl)pyridin-3-yl]-2-oxoimidazo[4,5-c]quinolin-1-yl]cyclohexyl]methanesulfonamide Chemical compound CN1C=C(C=N1)C1=CC=C(C=N1)C1=CC=C2N=CC3=C(N(C4CCC(CC4)NS(C)(=O)=O)C(=O)N3C)C2=C1 LYFAZDMTFHLILE-UHFFFAOYSA-N 0.000 claims description 3
- 125000002393 azetidinyl group Chemical group 0.000 claims description 3
- 206010012601 diabetes mellitus Diseases 0.000 claims description 3
- 208000016097 disease of metabolism Diseases 0.000 claims description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 3
- YTTYQCZIIFFOOD-UHFFFAOYSA-N 1-(1-benzylpyrrolidin-3-yl)-3-methyl-8-[6-(1-methylpyrazol-4-yl)pyridin-3-yl]imidazo[4,5-c]quinolin-2-one Chemical compound C(C1=CC=CC=C1)N1CC(CC1)N1C(N(C=2C=NC=3C=CC(=CC=3C=21)C=1C=NC(=CC=1)C=1C=NN(C=1)C)C)=O YTTYQCZIIFFOOD-UHFFFAOYSA-N 0.000 claims description 2
- MFSIQXZMMHNVJD-UHFFFAOYSA-N 1-(1-ethylpyrrolidin-3-yl)-3-methyl-8-[6-(1-methylpyrazol-4-yl)pyridin-3-yl]imidazo[4,5-c]quinolin-2-one Chemical compound C(C)N1CC(CC1)N1C(N(C=2C=NC=3C=CC(=CC=3C=21)C=1C=NC(=CC=1)C=1C=NN(C=1)C)C)=O MFSIQXZMMHNVJD-UHFFFAOYSA-N 0.000 claims description 2
- SXFALQAPCYABMN-UHFFFAOYSA-N 1-(3-hydroxycyclohexyl)-3-methyl-8-[6-(1-methylpyrazol-4-yl)pyridin-3-yl]imidazo[4,5-c]quinolin-2-one Chemical compound OC1CC(CCC1)N1C(N(C=2C=NC=3C=CC(=CC=3C=21)C=1C=NC(=CC=1)C=1C=NN(C=1)C)C)=O SXFALQAPCYABMN-UHFFFAOYSA-N 0.000 claims description 2
- UTRMKCYEJJWCFR-UHFFFAOYSA-N 1-(3-hydroxycyclopentyl)-3-methyl-8-[6-(1-methylpyrazol-4-yl)pyridin-3-yl]imidazo[4,5-c]quinolin-2-one Chemical compound OC1CC(CC1)N1C(N(C=2C=NC=3C=CC(=CC=3C=21)C=1C=NC(=CC=1)C=1C=NN(C=1)C)C)=O UTRMKCYEJJWCFR-UHFFFAOYSA-N 0.000 claims description 2
- UOSMVGWFXJJPLS-UHFFFAOYSA-N 1-(4-hydroxycyclohexyl)-3-methyl-8-(6-phenylpyridin-3-yl)imidazo[4,5-c]quinolin-2-one Chemical compound CN1C(=O)N(C2CCC(O)CC2)C2=C1C=NC1=CC=C(C=C21)C1=CC=C(N=C1)C1=CC=CC=C1 UOSMVGWFXJJPLS-UHFFFAOYSA-N 0.000 claims description 2
- UQAUUPWWWXZWJV-FQEVSTJZSA-N 1-[(3S)-1-ethylsulfonylpyrrolidin-3-yl]-3-methyl-8-[6-(1-methylpyrazol-4-yl)pyridin-3-yl]imidazo[4,5-c]quinolin-2-one Chemical compound C(C)S(=O)(=O)N1C[C@H](CC1)N1C(N(C=2C=NC=3C=CC(=CC=3C=21)C=1C=NC(=CC=1)C=1C=NN(C=1)C)C)=O UQAUUPWWWXZWJV-FQEVSTJZSA-N 0.000 claims description 2
- GDWGLJATTHZCKY-UHFFFAOYSA-N 1-[1-(2-hydroxyacetyl)pyrrolidin-3-yl]-3-methyl-8-[6-(1-methylpyrazol-4-yl)pyridin-3-yl]imidazo[4,5-c]quinolin-2-one Chemical compound OCC(=O)N1CC(CC1)N1C(N(C=2C=NC=3C=CC(=CC=3C=21)C=1C=NC(=CC=1)C=1C=NN(C=1)C)C)=O GDWGLJATTHZCKY-UHFFFAOYSA-N 0.000 claims description 2
- CDXWLONPIGDQIQ-UHFFFAOYSA-N 1-[1-(4-chlorophenyl)sulfonylpyrrolidin-3-yl]-3-methyl-8-[6-(1-methylpyrazol-4-yl)pyridin-3-yl]imidazo[4,5-c]quinolin-2-one Chemical compound ClC1=CC=C(C=C1)S(=O)(=O)N1CC(CC1)N1C(N(C=2C=NC=3C=CC(=CC=3C=21)C=1C=NC(=CC=1)C=1C=NN(C=1)C)C)=O CDXWLONPIGDQIQ-UHFFFAOYSA-N 0.000 claims description 2
- SUUMVCJDZHQGAX-PBVYKCSPSA-N 1-[1-[(2S)-2-hydroxypropanoyl]piperidin-3-yl]-3-methyl-8-[6-(1-methylpyrazol-4-yl)pyridin-3-yl]imidazo[4,5-c]quinolin-2-one Chemical compound O[C@H](C(=O)N1CC(CCC1)N1C(N(C=2C=NC=3C=CC(=CC=3C=21)C=1C=NC(=CC=1)C=1C=NN(C=1)C)C)=O)C SUUMVCJDZHQGAX-PBVYKCSPSA-N 0.000 claims description 2
- CYVVSUSKLSBKKE-UHFFFAOYSA-N 2-methyl-2-[4-[3-methyl-8-[6-(1-methylpyrazol-4-yl)pyridin-3-yl]-2-oxoimidazo[4,5-c]quinolin-1-yl]phenyl]propanoic acid Chemical compound CC(C(=O)O)(C)C1=CC=C(C=C1)N1C(N(C=2C=NC=3C=CC(=CC=3C=21)C=1C=NC(=CC=1)C=1C=NN(C=1)C)C)=O CYVVSUSKLSBKKE-UHFFFAOYSA-N 0.000 claims description 2
- NLYVZOHTEFTIMI-UHFFFAOYSA-N 3-methyl-1-(1-methylsulfonylpiperidin-4-yl)-8-[6-(1-methyltriazol-4-yl)pyridin-3-yl]imidazo[4,5-c]quinolin-2-one Chemical compound CN1C(N(C2=C1C=NC=1C=CC(=CC2=1)C=1C=NC(=CC=1)C=1N=NN(C=1)C)C1CCN(CC1)S(=O)(=O)C)=O NLYVZOHTEFTIMI-UHFFFAOYSA-N 0.000 claims description 2
- GYBYVSCYGPAFPU-NRFANRHFSA-N 3-methyl-1-[(3S)-1-methylsulfonylpyrrolidin-3-yl]-8-(6-phenylpyridin-3-yl)imidazo[4,5-c]quinolin-2-one Chemical compound CN1C(N(C2=C1C=NC=1C=CC(=CC2=1)C=1C=NC(=CC=1)C1=CC=CC=C1)[C@@H]1CN(CC1)S(=O)(=O)C)=O GYBYVSCYGPAFPU-NRFANRHFSA-N 0.000 claims description 2
- HHVRGSZZXUCNQT-SFHVURJKSA-N 3-methyl-1-[(3S)-1-methylsulfonylpyrrolidin-3-yl]-8-(6-pyrazol-1-ylpyridin-3-yl)imidazo[4,5-c]quinolin-2-one Chemical compound N1(N=CC=C1)C1=CC=C(C=N1)C1=CC=2C3=C(C=NC=2C=C1)N(C(N3[C@@H]1CN(CC1)S(=O)(=O)C)=O)C HHVRGSZZXUCNQT-SFHVURJKSA-N 0.000 claims description 2
- XGYKGRZVQMASLA-KRWDZBQOSA-N 3-methyl-1-[(3S)-1-methylsulfonylpyrrolidin-3-yl]-8-[6-(1,2,4-triazol-1-yl)pyridin-3-yl]imidazo[4,5-c]quinolin-2-one Chemical compound N1(N=CN=C1)C1=CC=C(C=N1)C1=CC=2C3=C(C=NC=2C=C1)N(C(N3[C@@H]1CN(CC1)S(=O)(=O)C)=O)C XGYKGRZVQMASLA-KRWDZBQOSA-N 0.000 claims description 2
- QRGDBCOFRWMBEQ-KRWDZBQOSA-N 3-methyl-1-[(3S)-1-methylsulfonylpyrrolidin-3-yl]-8-[6-(1-methyl-1,2,4-triazol-3-yl)pyridin-3-yl]imidazo[4,5-c]quinolin-2-one Chemical compound CN1C(N(C2=C1C=NC=1C=CC(=CC2=1)C=1C=NC(=CC=1)C1=NN(C=N1)C)[C@@H]1CN(CC1)S(=O)(=O)C)=O QRGDBCOFRWMBEQ-KRWDZBQOSA-N 0.000 claims description 2
- YWQFADUBIVLGFM-KRWDZBQOSA-N 3-methyl-1-[(3S)-1-methylsulfonylpyrrolidin-3-yl]-8-[6-(1-methyltriazol-4-yl)pyridin-3-yl]imidazo[4,5-c]quinolin-2-one Chemical compound CN1C(N(C2=C1C=NC=1C=CC(=CC2=1)C=1C=NC(=CC=1)C=1N=NN(C=1)C)[C@@H]1CN(CC1)S(=O)(=O)C)=O YWQFADUBIVLGFM-KRWDZBQOSA-N 0.000 claims description 2
- JGMYNOORRKKSCF-KRWDZBQOSA-N 3-methyl-1-[(3S)-1-methylsulfonylpyrrolidin-3-yl]-8-[6-(triazol-1-yl)pyridin-3-yl]imidazo[4,5-c]quinolin-2-one Chemical compound N1(N=NC=C1)C1=CC=C(C=N1)C1=CC=2C3=C(C=NC=2C=C1)N(C(N3[C@@H]1CN(CC1)S(=O)(=O)C)=O)C JGMYNOORRKKSCF-KRWDZBQOSA-N 0.000 claims description 2
- ROQAOXLNQMTAGN-UHFFFAOYSA-N 3-methyl-8-[6-(1-methylpyrazol-4-yl)pyridin-3-yl]-1-(8-methylsulfonyl-8-azabicyclo[3.2.1]octan-3-yl)imidazo[4,5-c]quinolin-2-one Chemical compound CN1C(N(C2=C1C=NC=1C=CC(=CC2=1)C=1C=NC(=CC=1)C=1C=NN(C=1)C)C1CC2CCC(C1)N2S(=O)(=O)C)=O ROQAOXLNQMTAGN-UHFFFAOYSA-N 0.000 claims description 2
- JZBYJCKMSJWMGC-LJQANCHMSA-N 3-methyl-8-[6-(1-methylpyrazol-4-yl)pyridin-3-yl]-1-[(3R)-1-(trifluoromethylsulfonyl)piperidin-3-yl]imidazo[4,5-c]quinolin-2-one Chemical compound CN1C(N(C2=C1C=NC=1C=CC(=CC2=1)C=1C=NC(=CC=1)C=1C=NN(C=1)C)[C@H]1CN(CCC1)S(=O)(=O)C(F)(F)F)=O JZBYJCKMSJWMGC-LJQANCHMSA-N 0.000 claims description 2
- VNVSMYNQNASCOA-HXUWFJFHSA-N 3-methyl-8-[6-(1-methylpyrazol-4-yl)pyridin-3-yl]-1-[(3R)-1-methylsulfonylpiperidin-3-yl]imidazo[4,5-c]quinolin-2-one Chemical compound CN1C(N(C2=C1C=NC=1C=CC(=CC2=1)C=1C=NC(=CC=1)C=1C=NN(C=1)C)[C@H]1CN(CCC1)S(=O)(=O)C)=O VNVSMYNQNASCOA-HXUWFJFHSA-N 0.000 claims description 2
- DXDMJBHDBWZXBF-LJQANCHMSA-N 3-methyl-8-[6-(1-methylpyrazol-4-yl)pyridin-3-yl]-1-[(3R)-1-methylsulfonylpyrrolidin-3-yl]imidazo[4,5-c]quinolin-2-one Chemical compound CN1C(N(C2=C1C=NC=1C=CC(=CC2=1)C=1C=NC(=CC=1)C=1C=NN(C=1)C)[C@H]1CN(CC1)S(=O)(=O)C)=O DXDMJBHDBWZXBF-LJQANCHMSA-N 0.000 claims description 2
- VKWWMCZYKPRMLI-UHFFFAOYSA-N 3-methyl-8-[6-(1-methylpyrazol-4-yl)pyridin-3-yl]-1-[1-(1H-1,2,4-triazole-5-carbonyl)piperidin-3-yl]imidazo[4,5-c]quinolin-2-one Chemical compound N1N=C(N=C1)C(=O)N1CC(CCC1)N1C(N(C=2C=NC=3C=CC(=CC=3C=21)C=1C=NC(=CC=1)C=1C=NN(C=1)C)C)=O VKWWMCZYKPRMLI-UHFFFAOYSA-N 0.000 claims description 2
- RRNAMWGXLKIINX-UHFFFAOYSA-N 4-[3-methyl-8-[6-(1-methylpyrazol-4-yl)pyridin-3-yl]-2-oxoimidazo[4,5-c]quinolin-1-yl]cyclohexane-1-carboxylic acid Chemical compound CN1C=C(C=N1)C1=CC=C(C=N1)C1=CC=C2N=CC3=C(N(C4CCC(CC4)C(O)=O)C(=O)N3C)C2=C1 RRNAMWGXLKIINX-UHFFFAOYSA-N 0.000 claims description 2
- YNLUHRFUSCAFFG-UHFFFAOYSA-N N-[2-[3-methyl-8-[6-(1-methylpyrazol-4-yl)pyridin-3-yl]-2-oxoimidazo[4,5-c]quinolin-1-yl]ethyl]methanesulfonamide Chemical compound CN1C(N(C2=C1C=NC=1C=CC(=CC2=1)C=1C=NC(=CC=1)C=1C=NN(C=1)C)CCNS(=O)(=O)C)=O YNLUHRFUSCAFFG-UHFFFAOYSA-N 0.000 claims description 2
- AQXKYGUPFRNYIE-UHFFFAOYSA-N N-[4-[3-methyl-8-[6-(1-methylpyrazol-4-yl)pyridin-3-yl]-2-oxoimidazo[4,5-c]quinolin-1-yl]cyclohexyl]acetamide Chemical compound CN1C=C(C=N1)C1=CC=C(C=N1)C1=CC=C2N=CC3=C(N(C4CCC(CC4)NC(C)=O)C(=O)N3C)C2=C1 AQXKYGUPFRNYIE-UHFFFAOYSA-N 0.000 claims description 2
- 208000008589 Obesity Diseases 0.000 claims description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 235000020824 obesity Nutrition 0.000 claims description 2
- 125000003386 piperidinyl group Chemical group 0.000 claims description 2
- 230000003796 beauty Effects 0.000 claims 3
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 3
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 2
- QPFBYTCBROGTLN-UHFFFAOYSA-N 3-methyl-8-[6-(1-methylpyrazol-4-yl)pyridin-3-yl]-1-[1-(1H-1,2,4-triazole-5-carbonyl)pyrrolidin-3-yl]imidazo[4,5-c]quinolin-2-one Chemical compound N1N=C(N=C1)C(=O)N1CC(CC1)N1C(N(C=2C=NC=3C=CC(=CC=3C=21)C=1C=NC(=CC=1)C=1C=NN(C=1)C)C)=O QPFBYTCBROGTLN-UHFFFAOYSA-N 0.000 claims 1
- 102000038030 PI3Ks Human genes 0.000 claims 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims 1
- 125000003226 pyrazolyl group Chemical group 0.000 claims 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 1536
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 429
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 252
- 238000006243 chemical reaction Methods 0.000 description 214
- 239000007787 solid Substances 0.000 description 214
- 239000012043 crude product Substances 0.000 description 207
- 239000000243 solution Substances 0.000 description 197
- 239000012074 organic phase Substances 0.000 description 191
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 160
- 239000008346 aqueous phase Substances 0.000 description 132
- 238000004809 thin layer chromatography Methods 0.000 description 119
- 239000002904 solvent Substances 0.000 description 117
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 111
- 238000003756 stirring Methods 0.000 description 109
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 99
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 98
- 239000000047 product Substances 0.000 description 94
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 93
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 90
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 80
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 77
- 238000010898 silica gel chromatography Methods 0.000 description 73
- 239000000203 mixture Substances 0.000 description 70
- 239000012299 nitrogen atmosphere Substances 0.000 description 65
- 239000005457 ice water Substances 0.000 description 64
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 54
- 239000003480 eluent Substances 0.000 description 54
- 125000004432 carbon atom Chemical group C* 0.000 description 52
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 51
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 46
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 44
- 239000000741 silica gel Substances 0.000 description 44
- 229910002027 silica gel Inorganic materials 0.000 description 44
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 42
- 229910000024 caesium carbonate Inorganic materials 0.000 description 42
- 239000000284 extract Substances 0.000 description 38
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 38
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 38
- 229910000029 sodium carbonate Inorganic materials 0.000 description 38
- 210000004027 cell Anatomy 0.000 description 33
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 31
- 125000003118 aryl group Chemical group 0.000 description 30
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 30
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 30
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 29
- 238000000034 method Methods 0.000 description 28
- 125000001072 heteroaryl group Chemical group 0.000 description 26
- 125000005842 heteroatom Chemical group 0.000 description 26
- 239000012453 solvate Substances 0.000 description 26
- 230000000694 effects Effects 0.000 description 25
- 239000007789 gas Substances 0.000 description 25
- 125000002950 monocyclic group Chemical group 0.000 description 24
- 239000000843 powder Substances 0.000 description 24
- 229920006395 saturated elastomer Polymers 0.000 description 23
- 102000009308 Mechanistic Target of Rapamycin Complex 2 Human genes 0.000 description 22
- 108010034057 Mechanistic Target of Rapamycin Complex 2 Proteins 0.000 description 22
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 22
- JRMUNVKIHCOMHV-UHFFFAOYSA-M tetrabutylammonium bromide Chemical compound [Br-].CCCC[N+](CCCC)(CCCC)CCCC JRMUNVKIHCOMHV-UHFFFAOYSA-M 0.000 description 21
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 20
- 125000000217 alkyl group Chemical group 0.000 description 20
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 20
- 238000010791 quenching Methods 0.000 description 20
- 108010035196 Mechanistic Target of Rapamycin Complex 1 Proteins 0.000 description 19
- 102000008135 Mechanistic Target of Rapamycin Complex 1 Human genes 0.000 description 19
- NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 19
- UCPYLLCMEDAXFR-UHFFFAOYSA-N triphosgene Chemical compound ClC(Cl)(Cl)OC(=O)OC(Cl)(Cl)Cl UCPYLLCMEDAXFR-UHFFFAOYSA-N 0.000 description 19
- 125000002619 bicyclic group Chemical group 0.000 description 17
- 125000000623 heterocyclic group Chemical group 0.000 description 17
- 239000012071 phase Substances 0.000 description 17
- 239000000651 prodrug Substances 0.000 description 16
- 229940002612 prodrug Drugs 0.000 description 16
- 230000015572 biosynthetic process Effects 0.000 description 15
- 229910052736 halogen Inorganic materials 0.000 description 15
- 150000002367 halogens Chemical class 0.000 description 15
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Chemical group C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 15
- 235000011056 potassium acetate Nutrition 0.000 description 15
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 14
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 14
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 description 14
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 14
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 14
- IPWKHHSGDUIRAH-UHFFFAOYSA-N bis(pinacolato)diboron Chemical compound O1C(C)(C)C(C)(C)OB1B1OC(C)(C)C(C)(C)O1 IPWKHHSGDUIRAH-UHFFFAOYSA-N 0.000 description 14
- 238000001035 drying Methods 0.000 description 14
- 239000012065 filter cake Substances 0.000 description 14
- 239000007788 liquid Substances 0.000 description 14
- 239000003208 petroleum Substances 0.000 description 14
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 14
- 108091008611 Protein Kinase B Proteins 0.000 description 13
- 229910052760 oxygen Inorganic materials 0.000 description 13
- 238000003786 synthesis reaction Methods 0.000 description 13
- 238000012360 testing method Methods 0.000 description 13
- 229940126214 compound 3 Drugs 0.000 description 12
- 239000000706 filtrate Substances 0.000 description 12
- 230000002829 reductive effect Effects 0.000 description 12
- GZNAASVAJNXPPW-UHFFFAOYSA-M tin(4+) chloride dihydrate Chemical compound O.O.[Cl-].[Sn+4] GZNAASVAJNXPPW-UHFFFAOYSA-M 0.000 description 12
- FWPIDFUJEMBDLS-UHFFFAOYSA-L tin(II) chloride dihydrate Substances O.O.Cl[Sn]Cl FWPIDFUJEMBDLS-UHFFFAOYSA-L 0.000 description 12
- 102000001253 Protein Kinase Human genes 0.000 description 11
- 108060006633 protein kinase Proteins 0.000 description 11
- 238000000746 purification Methods 0.000 description 11
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 11
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 10
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 10
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 10
- ZQWPRMPSCMSAJU-UHFFFAOYSA-N methyl cyclohexanecarboxylate Chemical compound COC(=O)C1CCCCC1 ZQWPRMPSCMSAJU-UHFFFAOYSA-N 0.000 description 10
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 9
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 9
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 9
- 241000124008 Mammalia Species 0.000 description 9
- 239000012267 brine Substances 0.000 description 9
- 230000010261 cell growth Effects 0.000 description 9
- 239000013078 crystal Substances 0.000 description 9
- 229910052757 nitrogen Inorganic materials 0.000 description 9
- 238000005191 phase separation Methods 0.000 description 9
- 239000002994 raw material Substances 0.000 description 9
- 238000000926 separation method Methods 0.000 description 9
- 235000017557 sodium bicarbonate Nutrition 0.000 description 9
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 9
- 208000024891 symptom Diseases 0.000 description 9
- 238000002877 time resolved fluorescence resonance energy transfer Methods 0.000 description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 8
- 108091000080 Phosphotransferase Proteins 0.000 description 8
- 230000004913 activation Effects 0.000 description 8
- 125000000304 alkynyl group Chemical group 0.000 description 8
- 125000003277 amino group Chemical group 0.000 description 8
- 125000004429 atom Chemical group 0.000 description 8
- 230000008859 change Effects 0.000 description 8
- 125000004433 nitrogen atom Chemical group N* 0.000 description 8
- 102000020233 phosphotransferase Human genes 0.000 description 8
- 125000001424 substituent group Chemical group 0.000 description 8
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 7
- 206010057249 Phagocytosis Diseases 0.000 description 7
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- 239000012141 concentrate Substances 0.000 description 7
- LWJYMKDMGMOTSB-UHFFFAOYSA-L dichlorotin;hydrate Chemical compound O.Cl[Sn]Cl LWJYMKDMGMOTSB-UHFFFAOYSA-L 0.000 description 7
- 238000001914 filtration Methods 0.000 description 7
- 239000001963 growth medium Substances 0.000 description 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 239000003921 oil Substances 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 7
- 239000000758 substrate Substances 0.000 description 7
- 229910052717 sulfur Inorganic materials 0.000 description 7
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 6
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 6
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 6
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 6
- 101150020518 RHEB gene Proteins 0.000 description 6
- 102000046951 Ras Homolog Enriched in Brain Human genes 0.000 description 6
- 108700019578 Ras Homolog Enriched in Brain Proteins 0.000 description 6
- 125000003342 alkenyl group Chemical group 0.000 description 6
- 229910052799 carbon Inorganic materials 0.000 description 6
- 239000006285 cell suspension Substances 0.000 description 6
- 238000012054 celltiter-glo Methods 0.000 description 6
- 125000004093 cyano group Chemical group *C#N 0.000 description 6
- 125000000753 cycloalkyl group Chemical group 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 239000002552 dosage form Substances 0.000 description 6
- 239000012091 fetal bovine serum Substances 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 230000004060 metabolic process Effects 0.000 description 6
- 230000008782 phagocytosis Effects 0.000 description 6
- 239000002244 precipitate Substances 0.000 description 6
- 230000019491 signal transduction Effects 0.000 description 6
- 230000004083 survival effect Effects 0.000 description 6
- LFKDJXLFVYVEFG-UHFFFAOYSA-N tert-butyl carbamate Chemical compound CC(C)(C)OC(N)=O LFKDJXLFVYVEFG-UHFFFAOYSA-N 0.000 description 6
- FQFILJKFZCVHNH-UHFFFAOYSA-N tert-butyl n-[3-[(5-bromo-2-chloropyrimidin-4-yl)amino]propyl]carbamate Chemical compound CC(C)(C)OC(=O)NCCCNC1=NC(Cl)=NC=C1Br FQFILJKFZCVHNH-UHFFFAOYSA-N 0.000 description 6
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 5
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical class [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 5
- 125000003545 alkoxy group Chemical group 0.000 description 5
- 230000004071 biological effect Effects 0.000 description 5
- 125000002837 carbocyclic group Chemical group 0.000 description 5
- 239000000460 chlorine Substances 0.000 description 5
- 238000001704 evaporation Methods 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 238000007689 inspection Methods 0.000 description 5
- 230000000670 limiting effect Effects 0.000 description 5
- 235000016709 nutrition Nutrition 0.000 description 5
- 238000005192 partition Methods 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 238000012746 preparative thin layer chromatography Methods 0.000 description 5
- 238000010992 reflux Methods 0.000 description 5
- 125000006413 ring segment Chemical group 0.000 description 5
- 230000011664 signaling Effects 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- 238000001291 vacuum drying Methods 0.000 description 5
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 4
- LJVQHXICFCZRJN-UHFFFAOYSA-N 1h-1,2,4-triazole-5-carboxylic acid Chemical compound OC(=O)C1=NC=NN1 LJVQHXICFCZRJN-UHFFFAOYSA-N 0.000 description 4
- HDECRAPHCDXMIJ-UHFFFAOYSA-N 2-methylbenzenesulfonyl chloride Chemical compound CC1=CC=CC=C1S(Cl)(=O)=O HDECRAPHCDXMIJ-UHFFFAOYSA-N 0.000 description 4
- 102000014914 Carrier Proteins Human genes 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 4
- JVTAAEKCZFNVCJ-REOHCLBHSA-N L-lactic acid Chemical compound C[C@H](O)C(O)=O JVTAAEKCZFNVCJ-REOHCLBHSA-N 0.000 description 4
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical group C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 4
- 108010074436 Sterol Regulatory Element Binding Protein 1 Proteins 0.000 description 4
- 102100026839 Sterol regulatory element-binding protein 1 Human genes 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 108091008324 binding proteins Proteins 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 150000001721 carbon Chemical group 0.000 description 4
- HPXRVTGHNJAIIH-UHFFFAOYSA-N cyclohexanol Chemical compound OC1CCCCC1 HPXRVTGHNJAIIH-UHFFFAOYSA-N 0.000 description 4
- SNRCKKQHDUIRIY-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloromethane;dichloropalladium;iron(2+) Chemical compound [Fe+2].ClCCl.Cl[Pd]Cl.C1=C[CH-]C(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.C1=C[CH-]C(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 SNRCKKQHDUIRIY-UHFFFAOYSA-L 0.000 description 4
- 230000029087 digestion Effects 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 229910052731 fluorine Inorganic materials 0.000 description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 4
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 4
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 229910000104 sodium hydride Inorganic materials 0.000 description 4
- 125000000547 substituted alkyl group Chemical group 0.000 description 4
- 239000012085 test solution Substances 0.000 description 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 4
- KOOLGTNMOAXCDL-UHFFFAOYSA-N 1-(4-hydroxycyclohexyl)-3-methyl-8-[6-(1-methylpyrazol-4-yl)pyridin-3-yl]imidazo[4,5-c]quinolin-2-one Chemical compound CN1C=C(C=N1)C1=CC=C(C=N1)C1=CC=C2N=CC3=C(N(C4CCC(O)CC4)C(=O)N3C)C2=C1 KOOLGTNMOAXCDL-UHFFFAOYSA-N 0.000 description 3
- LHZGKXZYXXZNAY-UHFFFAOYSA-N 3-methyl-8-[6-(1-methylpyrazol-4-yl)pyridin-3-yl]-1-piperidin-3-ylimidazo[4,5-c]quinolin-2-one Chemical compound CN1C(N(C2=C1C=NC=1C=CC(=CC2=1)C=1C=NC(=CC=1)C=1C=NN(C=1)C)C1CNCCC1)=O LHZGKXZYXXZNAY-UHFFFAOYSA-N 0.000 description 3
- 125000004364 3-pyrrolinyl group Chemical group [H]C1=C([H])C([H])([H])N(*)C1([H])[H] 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102100022466 Eukaryotic translation initiation factor 4E-binding protein 1 Human genes 0.000 description 3
- 108050000946 Eukaryotic translation initiation factor 4E-binding protein 1 Proteins 0.000 description 3
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 3
- 101000864800 Homo sapiens Serine/threonine-protein kinase Sgk1 Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 3
- 229920001213 Polysorbate 20 Polymers 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- 102100030070 Serine/threonine-protein kinase Sgk1 Human genes 0.000 description 3
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 3
- 230000001093 anti-cancer Effects 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 3
- 229910052794 bromium Inorganic materials 0.000 description 3
- 239000001569 carbon dioxide Substances 0.000 description 3
- 229910002092 carbon dioxide Inorganic materials 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 229910052801 chlorine Inorganic materials 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 229940125898 compound 5 Drugs 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 3
- 239000011737 fluorine Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 150000002430 hydrocarbons Chemical class 0.000 description 3
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- 239000011259 mixed solution Substances 0.000 description 3
- 239000012046 mixed solvent Substances 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 3
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 3
- 125000002755 pyrazolinyl group Chemical group 0.000 description 3
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 3
- 239000012312 sodium hydride Substances 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
- IRFHMTUHTBSEBK-QGZVFWFLSA-N tert-butyl n-[(2s)-2-(2,5-difluorophenyl)-3-quinolin-3-ylpropyl]carbamate Chemical compound C1([C@H](CC=2C=C3C=CC=CC3=NC=2)CNC(=O)OC(C)(C)C)=CC(F)=CC=C1F IRFHMTUHTBSEBK-QGZVFWFLSA-N 0.000 description 3
- RQCNHUCCQJMSRG-UHFFFAOYSA-N tert-butyl piperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCCCC1 RQCNHUCCQJMSRG-UHFFFAOYSA-N 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 125000003396 thiol group Chemical group [H]S* 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 238000011144 upstream manufacturing Methods 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 239000012224 working solution Substances 0.000 description 3
- SHAHPWSYJFYMRX-GDLCADMTSA-N (2S)-2-(4-{[(1R,2S)-2-hydroxycyclopentyl]methyl}phenyl)propanoic acid Chemical compound C1=CC([C@@H](C(O)=O)C)=CC=C1C[C@@H]1[C@@H](O)CCC1 SHAHPWSYJFYMRX-GDLCADMTSA-N 0.000 description 2
- OXEQYUJZRLTXIH-UHFFFAOYSA-N 1-(4-hydroxy-4-methylcyclohexyl)-3-methyl-8-[6-(1-methylpyrazol-4-yl)pyridin-3-yl]imidazo[4,5-c]quinolin-2-one Chemical compound OC1(CCC(CC1)N1C(N(C=2C=NC=3C=CC(=CC=3C=21)C=1C=NC(=CC=1)C=1C=NN(C=1)C)C)=O)C OXEQYUJZRLTXIH-UHFFFAOYSA-N 0.000 description 2
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 2
- FCEHBMOGCRZNNI-UHFFFAOYSA-N 1-benzothiophene Chemical compound C1=CC=C2SC=CC2=C1 FCEHBMOGCRZNNI-UHFFFAOYSA-N 0.000 description 2
- HBEDSQVIWPRPAY-UHFFFAOYSA-N 2,3-dihydrobenzofuran Chemical compound C1=CC=C2OCCC2=C1 HBEDSQVIWPRPAY-UHFFFAOYSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- ABPJMGXOUVQILW-IBGZPJMESA-N 3-methyl-1-[(3S)-1-methylsulfonylpyrrolidin-3-yl]-8-(6-phenylpyridin-3-yl)imidazo[4,5-c][1,5]naphthyridin-2-one Chemical compound CN1C(N(C2=C1C=NC=1C=CC(=NC2=1)C=1C=NC(=CC=1)C1=CC=CC=C1)[C@@H]1CN(CC1)S(=O)(=O)C)=O ABPJMGXOUVQILW-IBGZPJMESA-N 0.000 description 2
- WHTSBMSQTGKAIG-UHFFFAOYSA-N 3-methyl-8-[6-(1-methylpyrazol-4-yl)pyridin-3-yl]-1-(1-methylsulfonylpiperidin-3-yl)imidazo[4,5-c][1,5]naphthyridin-2-one Chemical compound CN1C(N(C2=C1C=NC=1C=CC(=NC2=1)C=1C=NC(=CC=1)C=1C=NN(C=1)C)C1CN(CCC1)S(=O)(=O)C)=O WHTSBMSQTGKAIG-UHFFFAOYSA-N 0.000 description 2
- DXDMJBHDBWZXBF-IBGZPJMESA-N 3-methyl-8-[6-(1-methylpyrazol-4-yl)pyridin-3-yl]-1-[(3S)-1-methylsulfonylpyrrolidin-3-yl]imidazo[4,5-c]quinolin-2-one Chemical compound CN1C(N(C2=C1C=NC=1C=CC(=CC2=1)C=1C=NC(=CC=1)C=1C=NN(C=1)C)[C@@H]1CN(CC1)S(=O)(=O)C)=O DXDMJBHDBWZXBF-IBGZPJMESA-N 0.000 description 2
- 125000004575 3-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- IMLXLGZJLAOKJN-UHFFFAOYSA-N 4-aminocyclohexan-1-ol Chemical compound NC1CCC(O)CC1 IMLXLGZJLAOKJN-UHFFFAOYSA-N 0.000 description 2
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 2
- 125000001826 4H-pyranyl group Chemical group O1C(=CCC=C1)* 0.000 description 2
- PRNGIODVYLTUKH-UHFFFAOYSA-N 5-bromo-2-phenylpyridine Chemical compound N1=CC(Br)=CC=C1C1=CC=CC=C1 PRNGIODVYLTUKH-UHFFFAOYSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- UJOBWOGCFQCDNV-UHFFFAOYSA-N 9H-carbazole Chemical compound C1=CC=C2C3=CC=CC=C3NC2=C1 UJOBWOGCFQCDNV-UHFFFAOYSA-N 0.000 description 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 208000005623 Carcinogenesis Diseases 0.000 description 2
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 2
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- 206010029113 Neovascularisation Diseases 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 102100024924 Protein kinase C alpha type Human genes 0.000 description 2
- 101710109947 Protein kinase C alpha type Proteins 0.000 description 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical group C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- 239000012979 RPMI medium Substances 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229910052771 Terbium Inorganic materials 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 2
- 229910021626 Tin(II) chloride Inorganic materials 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 125000002723 alicyclic group Chemical group 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 125000004414 alkyl thio group Chemical group 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 229940041181 antineoplastic drug Drugs 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000012131 assay buffer Substances 0.000 description 2
- 238000011001 backwashing Methods 0.000 description 2
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 description 2
- 230000036952 cancer formation Effects 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 231100000504 carcinogenesis Toxicity 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000022131 cell cycle Effects 0.000 description 2
- 230000019522 cellular metabolic process Effects 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 125000000392 cycloalkenyl group Chemical group 0.000 description 2
- NZNMSOFKMUBTKW-UHFFFAOYSA-N cyclohexanecarboxylic acid Chemical compound OC(=O)C1CCCCC1 NZNMSOFKMUBTKW-UHFFFAOYSA-N 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 125000004663 dialkyl amino group Chemical group 0.000 description 2
- 229910001873 dinitrogen Inorganic materials 0.000 description 2
- 125000000532 dioxanyl group Chemical group 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 125000005883 dithianyl group Chemical group 0.000 description 2
- 238000009510 drug design Methods 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- FRYHCSODNHYDPU-UHFFFAOYSA-N ethanesulfonyl chloride Chemical compound CCS(Cl)(=O)=O FRYHCSODNHYDPU-UHFFFAOYSA-N 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 229960004275 glycolic acid Drugs 0.000 description 2
- 239000005090 green fluorescent protein Substances 0.000 description 2
- 125000001188 haloalkyl group Chemical group 0.000 description 2
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 201000001421 hyperglycemia Diseases 0.000 description 2
- 125000002636 imidazolinyl group Chemical group 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 2
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
- 229940124302 mTOR inhibitor Drugs 0.000 description 2
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- OKKJLVBELUTLKV-VMNATFBRSA-N methanol-d1 Chemical compound [2H]OC OKKJLVBELUTLKV-VMNATFBRSA-N 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 102000027450 oncoproteins Human genes 0.000 description 2
- 108091008819 oncoproteins Proteins 0.000 description 2
- 125000003551 oxepanyl group Chemical group 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 230000000865 phosphorylative effect Effects 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- FGIUAXJPYTZDNR-UHFFFAOYSA-N potassium nitrate Chemical compound [K+].[O-][N+]([O-])=O FGIUAXJPYTZDNR-UHFFFAOYSA-N 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- KSAVQLQVUXSOCR-UHFFFAOYSA-M sodium lauroyl sarcosinate Chemical compound [Na+].CCCCCCCCCCCC(=O)N(C)CC([O-])=O KSAVQLQVUXSOCR-UHFFFAOYSA-M 0.000 description 2
- 125000003003 spiro group Chemical group 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 229940124530 sulfonamide Drugs 0.000 description 2
- 150000003456 sulfonamides Chemical class 0.000 description 2
- 125000004434 sulfur atom Chemical group 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- GZCRRIHWUXGPOV-UHFFFAOYSA-N terbium atom Chemical compound [Tb] GZCRRIHWUXGPOV-UHFFFAOYSA-N 0.000 description 2
- 150000003536 tetrazoles Chemical group 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- 238000012384 transportation and delivery Methods 0.000 description 2
- 125000004306 triazinyl group Chemical group 0.000 description 2
- WJKHJLXJJJATHN-UHFFFAOYSA-N triflic anhydride Chemical compound FC(F)(F)S(=O)(=O)OS(=O)(=O)C(F)(F)F WJKHJLXJJJATHN-UHFFFAOYSA-N 0.000 description 2
- 230000005740 tumor formation Effects 0.000 description 2
- VIMMECPCYZXUCI-MIMFYIINSA-N (4s,6r)-6-[(1e)-4,4-bis(4-fluorophenyl)-3-(1-methyltetrazol-5-yl)buta-1,3-dienyl]-4-hydroxyoxan-2-one Chemical compound CN1N=NN=C1C(\C=C\[C@@H]1OC(=O)C[C@@H](O)C1)=C(C=1C=CC(F)=CC=1)C1=CC=C(F)C=C1 VIMMECPCYZXUCI-MIMFYIINSA-N 0.000 description 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 1
- FNQJDLTXOVEEFB-UHFFFAOYSA-N 1,2,3-benzothiadiazole Chemical group C1=CC=C2SN=NC2=C1 FNQJDLTXOVEEFB-UHFFFAOYSA-N 0.000 description 1
- SLLFVLKNXABYGI-UHFFFAOYSA-N 1,2,3-benzoxadiazole Chemical group C1=CC=C2ON=NC2=C1 SLLFVLKNXABYGI-UHFFFAOYSA-N 0.000 description 1
- JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical compound C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 description 1
- YGTAZGSLCXNBQL-UHFFFAOYSA-N 1,2,4-thiadiazole Chemical compound C=1N=CSN=1 YGTAZGSLCXNBQL-UHFFFAOYSA-N 0.000 description 1
- CIISBYKBBMFLEZ-UHFFFAOYSA-N 1,2-oxazolidine Chemical compound C1CNOC1 CIISBYKBBMFLEZ-UHFFFAOYSA-N 0.000 description 1
- CZSRXHJVZUBEGW-UHFFFAOYSA-N 1,2-thiazolidine Chemical compound C1CNSC1 CZSRXHJVZUBEGW-UHFFFAOYSA-N 0.000 description 1
- FTNJQNQLEGKTGD-UHFFFAOYSA-N 1,3-benzodioxole Chemical compound C1=CC=C2OCOC2=C1 FTNJQNQLEGKTGD-UHFFFAOYSA-N 0.000 description 1
- 125000000355 1,3-benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- IGERFAHWSHDDHX-UHFFFAOYSA-N 1,3-dioxanyl Chemical group [CH]1OCCCO1 IGERFAHWSHDDHX-UHFFFAOYSA-N 0.000 description 1
- OGYGFUAIIOPWQD-UHFFFAOYSA-N 1,3-thiazolidine Chemical compound C1CSCN1 OGYGFUAIIOPWQD-UHFFFAOYSA-N 0.000 description 1
- IBXMKLPFLZYRQZ-UHFFFAOYSA-N 1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1C=CC(=O)C=CC1=CC=CC=C1 IBXMKLPFLZYRQZ-UHFFFAOYSA-N 0.000 description 1
- SXVXNRBQPBGBLP-UHFFFAOYSA-N 1-(2-aminoethyl)-3-methyl-8-[6-(1-methylpyrazol-4-yl)pyridin-3-yl]imidazo[4,5-c]quinolin-2-one Chemical compound NCCN1C(N(C=2C=NC=3C=CC(=CC=3C=21)C=1C=NC(=CC=1)C=1C=NN(C=1)C)C)=O SXVXNRBQPBGBLP-UHFFFAOYSA-N 0.000 description 1
- IWWZJMKINULDRT-UHFFFAOYSA-N 1-(4-hydroxycyclohexyl)-3-methyl-8-(1-phenylpyrazol-4-yl)imidazo[4,5-c]quinolin-2-one Chemical compound CN1C(=O)N(C2CCC(O)CC2)C2=C1C=NC1=CC=C(C=C21)C1=CN(N=C1)C1=CC=CC=C1 IWWZJMKINULDRT-UHFFFAOYSA-N 0.000 description 1
- ONTKCWMBCSHUAZ-UHFFFAOYSA-N 1-(4-hydroxycyclohexyl)-3-methyl-8-(6-methylpyridin-3-yl)imidazo[4,5-c]quinolin-2-one Chemical compound CN1C(=O)N(C2CCC(O)CC2)C2=C1C=NC1=CC=C(C=C21)C1=CC=C(C)N=C1 ONTKCWMBCSHUAZ-UHFFFAOYSA-N 0.000 description 1
- ODLSLXILHHGLEI-UHFFFAOYSA-N 1-(8-azabicyclo[3.2.1]octan-3-yl)-3-methyl-8-[6-(1-methylpyrazol-4-yl)pyridin-3-yl]imidazo[4,5-c]quinolin-2-one Chemical compound C12CC(CC(CC1)N2)N1C(N(C=2C=NC=3C=CC(=CC=3C=21)C=1C=NC(=CC=1)C=1C=NN(C=1)C)C)=O ODLSLXILHHGLEI-UHFFFAOYSA-N 0.000 description 1
- SZPWSFCMQZVYRN-UHFFFAOYSA-N 1-(azetidin-3-yl)-3-methyl-8-[6-(1-methylpyrazol-4-yl)pyridin-3-yl]imidazo[4,5-c]quinolin-2-one Chemical compound N1CC(C1)N1C(N(C=2C=NC=3C=CC(=CC=3C=21)C=1C=NC(=CC=1)C=1C=NN(C=1)C)C)=O SZPWSFCMQZVYRN-UHFFFAOYSA-N 0.000 description 1
- XTVYXPOVHPUUNC-UHFFFAOYSA-N 1-amino-3-(3-amino-6-bromoquinolin-4-yl)cyclopentan-1-ol Chemical compound NC=1C=NC2=CC=C(C=C2C=1C1CC(CC1)(O)N)Br XTVYXPOVHPUUNC-UHFFFAOYSA-N 0.000 description 1
- BGIYWPKHILWLDX-UHFFFAOYSA-N 1-amino-3-(6-bromo-3-nitroquinolin-4-yl)cyclopentan-1-ol Chemical compound BrC=1C=C2C(=C(C=NC2=CC=1)[N+](=O)[O-])C1CC(CC1)(O)N BGIYWPKHILWLDX-UHFFFAOYSA-N 0.000 description 1
- ZNRLSDRSVBEBMA-UHFFFAOYSA-N 1-methylsulfonylpyrrole Chemical compound CS(=O)(=O)N1C=CC=C1 ZNRLSDRSVBEBMA-UHFFFAOYSA-N 0.000 description 1
- JWAWEQBUZOGIBZ-UHFFFAOYSA-N 1-methyltriazole Chemical compound CN1C=CN=N1 JWAWEQBUZOGIBZ-UHFFFAOYSA-N 0.000 description 1
- XPAJFLOIPDXRRD-UHFFFAOYSA-N 1-phenyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole Chemical compound O1C(C)(C)C(C)(C)OB1C1=CN(C=2C=CC=CC=2)N=C1 XPAJFLOIPDXRRD-UHFFFAOYSA-N 0.000 description 1
- 125000006017 1-propenyl group Chemical group 0.000 description 1
- QWENRTYMTSOGBR-UHFFFAOYSA-N 1H-1,2,3-Triazole Chemical compound C=1C=NNN=1 QWENRTYMTSOGBR-UHFFFAOYSA-N 0.000 description 1
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 1
- XAWPKHNOFIWWNZ-UHFFFAOYSA-N 1h-indol-6-ol Chemical group OC1=CC=C2C=CNC2=C1 XAWPKHNOFIWWNZ-UHFFFAOYSA-N 0.000 description 1
- AMFYRKOUWBAGHV-UHFFFAOYSA-N 1h-pyrazolo[4,3-b]pyridine Chemical compound C1=CN=C2C=NNC2=C1 AMFYRKOUWBAGHV-UHFFFAOYSA-N 0.000 description 1
- XWIYUCRMWCHYJR-UHFFFAOYSA-N 1h-pyrrolo[3,2-b]pyridine Chemical compound C1=CC=C2NC=CC2=N1 XWIYUCRMWCHYJR-UHFFFAOYSA-N 0.000 description 1
- GECCKOMBWFQPNY-UHFFFAOYSA-N 2,8-dichloro-7-nitro-1,5-naphthyridine Chemical compound C1=CC(Cl)=NC2=C(Cl)C([N+](=O)[O-])=CN=C21 GECCKOMBWFQPNY-UHFFFAOYSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- CUKXRHLWPSBCTI-UHFFFAOYSA-N 2-amino-5-bromobenzoic acid Chemical compound NC1=CC=C(Br)C=C1C(O)=O CUKXRHLWPSBCTI-UHFFFAOYSA-N 0.000 description 1
- 125000000069 2-butynyl group Chemical group [H]C([H])([H])C#CC([H])([H])* 0.000 description 1
- ILYKOEOLSBVPAC-UHFFFAOYSA-N 2-methoxy-3-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine Chemical compound C1=C(C)C(OC)=NC=C1B1OC(C)(C)C(C)(C)O1 ILYKOEOLSBVPAC-UHFFFAOYSA-N 0.000 description 1
- 125000004918 2-methyl-2-pentyl group Chemical group CC(C)(CCC)* 0.000 description 1
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- YQCISFRTGZYLBI-UHFFFAOYSA-N 3-[(3-amino-6-bromoquinolin-4-yl)amino]cyclohexan-1-ol Chemical compound NC=1C=NC2=CC=C(C=C2C=1NC1CC(CCC1)O)Br YQCISFRTGZYLBI-UHFFFAOYSA-N 0.000 description 1
- MBHNZNFOAXQWGD-UHFFFAOYSA-N 3-[(6-bromo-3-nitroquinolin-4-yl)amino]cyclohexan-1-ol Chemical compound BrC=1C=C2C(=C(C=NC2=CC=1)[N+](=O)[O-])NC1CC(CCC1)O MBHNZNFOAXQWGD-UHFFFAOYSA-N 0.000 description 1
- NIQIPYGXPZUDDP-UHFFFAOYSA-N 3-aminocyclohexan-1-ol Chemical compound NC1CCCC(O)C1 NIQIPYGXPZUDDP-UHFFFAOYSA-N 0.000 description 1
- SGKRJNWIEGYWGE-UHFFFAOYSA-N 3-aminocyclopentan-1-ol;hydrochloride Chemical compound Cl.NC1CCC(O)C1 SGKRJNWIEGYWGE-UHFFFAOYSA-N 0.000 description 1
- FIRJEWYMYWXQNB-UHFFFAOYSA-N 3-methyl-1-(8-methylsulfonyl-8-azabicyclo[3.2.1]octan-3-yl)-8-[6-(1-methyltriazol-4-yl)pyridin-3-yl]imidazo[4,5-c]quinolin-2-one Chemical compound CN1C(N(C2=C1C=NC=1C=CC(=CC2=1)C=1C=NC(=CC=1)C=1N=NN(C=1)C)C1CC2CCC(C1)N2S(=O)(=O)C)=O FIRJEWYMYWXQNB-UHFFFAOYSA-N 0.000 description 1
- TXDVWHNRKCELPU-HNNXBMFYSA-N 3-methyl-1-[(3S)-1-methylsulfonylpyrrolidin-3-yl]-8-[6-(1-methyltriazol-4-yl)pyridin-3-yl]imidazo[4,5-c][1,5]naphthyridin-2-one Chemical compound CN1C(N(C2=C1C=NC=1C=CC(=NC2=1)C=1C=NC(=CC=1)C=1N=NN(C=1)C)[C@@H]1CN(CC1)S(=O)(=O)C)=O TXDVWHNRKCELPU-HNNXBMFYSA-N 0.000 description 1
- OXERXEWBXJLBAQ-INIZCTEOSA-N 3-methyl-1-[(3S)-pyrrolidin-3-yl]-8-[6-(1,2,4-triazol-1-yl)pyridin-3-yl]imidazo[4,5-c]quinolin-2-one Chemical compound N1(N=CN=C1)C1=CC=C(C=N1)C1=CC=2C3=C(C=NC=2C=C1)N(C(N3[C@@H]1CNCC1)=O)C OXERXEWBXJLBAQ-INIZCTEOSA-N 0.000 description 1
- ZWJSZYTWLYEAPI-INIZCTEOSA-N 3-methyl-1-[(3S)-pyrrolidin-3-yl]-8-[6-(triazol-1-yl)pyridin-3-yl]imidazo[4,5-c]quinolin-2-one Chemical compound N1(N=NC=C1)C1=CC=C(C=N1)C1=CC=2C3=C(C=NC=2C=C1)N(C(N3[C@@H]1CNCC1)=O)C ZWJSZYTWLYEAPI-INIZCTEOSA-N 0.000 description 1
- 125000004919 3-methyl-2-pentyl group Chemical group CC(C(C)*)CC 0.000 description 1
- MIDFTVRKMGSIRK-LADVQKINSA-N 3-methyl-8-(6-phenylpiperidin-3-yl)-1-[(3S)-pyrrolidin-3-yl]imidazo[4,5-c]quinolin-2-one hydrochloride Chemical compound Cl.Cn1c2cnc3ccc(cc3c2n([C@H]2CCNC2)c1=O)C1CCC(NC1)c1ccccc1 MIDFTVRKMGSIRK-LADVQKINSA-N 0.000 description 1
- LXWYRVVOWTZRLN-SFHVURJKSA-N 3-methyl-8-(6-phenylpyridin-3-yl)-1-[(3S)-pyrrolidin-3-yl]imidazo[4,5-c][1,5]naphthyridin-2-one Chemical compound CN1C(N(C2=C1C=NC=1C=CC(=NC2=1)C=1C=NC(=CC=1)C1=CC=CC=C1)[C@@H]1CNCC1)=O LXWYRVVOWTZRLN-SFHVURJKSA-N 0.000 description 1
- ZIZUSBFPFXQTHX-INIZCTEOSA-N 3-methyl-8-[6-(1-methyl-1,2,4-triazol-3-yl)pyridin-3-yl]-1-[(3S)-pyrrolidin-3-yl]imidazo[4,5-c]quinolin-2-one Chemical compound CN1N=C(N=C1)C1=CC=C(C=N1)C1=CC=2C3=C(C=NC=2C=C1)N(C(N3[C@@H]1CNCC1)=O)C ZIZUSBFPFXQTHX-INIZCTEOSA-N 0.000 description 1
- RZDMZJQCDRAMOZ-KRWDZBQOSA-N 3-methyl-8-[6-(1-methylpyrazol-3-yl)pyridin-3-yl]-1-[(3S)-pyrrolidin-3-yl]imidazo[4,5-c]quinolin-2-one Chemical compound CN1C(N(C2=C1C=NC=1C=CC(=CC2=1)C=1C=NC(=CC=1)C1=NN(C=C1)C)[C@@H]1CNCC1)=O RZDMZJQCDRAMOZ-KRWDZBQOSA-N 0.000 description 1
- WHTSBMSQTGKAIG-GOSISDBHSA-N 3-methyl-8-[6-(1-methylpyrazol-4-yl)pyridin-3-yl]-1-[(3R)-1-methylsulfonylpiperidin-3-yl]imidazo[4,5-c][1,5]naphthyridin-2-one Chemical compound CN1C(N(C2=C1C=NC=1C=CC(=NC2=1)C=1C=NC(=CC=1)C=1C=NN(C=1)C)[C@H]1CN(CCC1)S(=O)(=O)C)=O WHTSBMSQTGKAIG-GOSISDBHSA-N 0.000 description 1
- MCYKEVVQIQIJPQ-QGZVFWFLSA-N 3-methyl-8-[6-(1-methylpyrazol-4-yl)pyridin-3-yl]-1-[(3R)-piperidin-3-yl]imidazo[4,5-c][1,5]naphthyridin-2-one Chemical compound CN1C(N(C2=C1C=NC=1C=CC(=NC2=1)C=1C=NC(=CC=1)C=1C=NN(C=1)C)[C@H]1CNCCC1)=O MCYKEVVQIQIJPQ-QGZVFWFLSA-N 0.000 description 1
- IYWAKMJZYQPYFL-GMUIIQOCSA-N 3-methyl-8-[6-(1-methylpyrazol-4-yl)pyridin-3-yl]-1-[(3R)-pyrrolidin-3-yl]imidazo[4,5-c]quinolin-2-one hydrochloride Chemical compound Cl.Cn1cc(cn1)-c1ccc(cn1)-c1ccc2ncc3n(C)c(=O)n([C@@H]4CCNC4)c3c2c1 IYWAKMJZYQPYFL-GMUIIQOCSA-N 0.000 description 1
- ISFAMBMLFVNBNT-KRWDZBQOSA-N 3-methyl-8-[6-(1-methylpyrazol-4-yl)pyridin-3-yl]-1-[(3S)-1-methylsulfonylpyrrolidin-3-yl]imidazo[4,5-c][1,5]naphthyridin-2-one Chemical compound CN1C(N(C2=C1C=NC=1C=CC(=NC2=1)C=1C=NC(=CC=1)C=1C=NN(C=1)C)[C@@H]1CN(CC1)S(=O)(=O)C)=O ISFAMBMLFVNBNT-KRWDZBQOSA-N 0.000 description 1
- RKRSXPBQVUONOW-INIZCTEOSA-N 3-methyl-8-[6-(1-methylpyrazol-4-yl)pyridin-3-yl]-1-[(3S)-pyrrolidin-3-yl]imidazo[4,5-c][1,5]naphthyridin-2-one Chemical compound CN1C(N(C2=C1C=NC=1C=CC(=NC2=1)C=1C=NC(=CC=1)C=1C=NN(C=1)C)[C@@H]1CNCC1)=O RKRSXPBQVUONOW-INIZCTEOSA-N 0.000 description 1
- IYWAKMJZYQPYFL-FERBBOLQSA-N 3-methyl-8-[6-(1-methylpyrazol-4-yl)pyridin-3-yl]-1-[(3S)-pyrrolidin-3-yl]imidazo[4,5-c]quinolin-2-one hydrochloride Chemical compound Cl.Cn1cc(cn1)-c1ccc(cn1)-c1ccc2ncc3n(C)c(=O)n([C@H]4CCNC4)c3c2c1 IYWAKMJZYQPYFL-FERBBOLQSA-N 0.000 description 1
- MCYKEVVQIQIJPQ-UHFFFAOYSA-N 3-methyl-8-[6-(1-methylpyrazol-4-yl)pyridin-3-yl]-1-piperidin-3-ylimidazo[4,5-c][1,5]naphthyridin-2-one Chemical compound CN1C(N(C2=C1C=NC=1C=CC(=NC2=1)C=1C=NC(=CC=1)C=1C=NN(C=1)C)C1CNCCC1)=O MCYKEVVQIQIJPQ-UHFFFAOYSA-N 0.000 description 1
- GTEFDUKTKRFPPU-UHFFFAOYSA-N 3-methyl-8-[6-(1-methylpyrazol-4-yl)pyridin-3-yl]-1-piperidin-4-ylimidazo[4,5-c]quinolin-2-one Chemical compound CN1C(N(C2=C1C=NC=1C=CC(=CC2=1)C=1C=NC(=CC=1)C=1C=NN(C=1)C)C1CCNCC1)=O GTEFDUKTKRFPPU-UHFFFAOYSA-N 0.000 description 1
- IYWAKMJZYQPYFL-UHFFFAOYSA-N 3-methyl-8-[6-(1-methylpyrazol-4-yl)pyridin-3-yl]-1-pyrrolidin-3-ylimidazo[4,5-c]quinolin-2-one hydrochloride Chemical compound Cl.Cn1cc(cn1)-c1ccc(cn1)-c1ccc2ncc3n(C)c(=O)n(C4CCNC4)c3c2c1 IYWAKMJZYQPYFL-UHFFFAOYSA-N 0.000 description 1
- DVGJTOYAZYFUGB-QGZVFWFLSA-N 3-methyl-8-[6-(1-methyltriazol-4-yl)pyridin-3-yl]-1-[(3R)-piperidin-3-yl]imidazo[4,5-c]quinolin-2-one Chemical compound CN1C(N(C2=C1C=NC=1C=CC(=CC2=1)C=1C=NC(=CC=1)C=1N=NN(C=1)C)[C@H]1CNCCC1)=O DVGJTOYAZYFUGB-QGZVFWFLSA-N 0.000 description 1
- FHYJKRRIVAKMRJ-AWEZNQCLSA-N 3-methyl-8-[6-(1-methyltriazol-4-yl)pyridin-3-yl]-1-[(3S)-pyrrolidin-3-yl]imidazo[4,5-c][1,5]naphthyridin-2-one Chemical compound CN1C(N(C2=C1C=NC=1C=CC(=NC2=1)C=1C=NC(=CC=1)C=1N=NN(C=1)C)[C@@H]1CNCC1)=O FHYJKRRIVAKMRJ-AWEZNQCLSA-N 0.000 description 1
- VUQNBJZDFINTTO-INIZCTEOSA-N 3-methyl-8-[6-(1-methyltriazol-4-yl)pyridin-3-yl]-1-[(3S)-pyrrolidin-3-yl]imidazo[4,5-c]quinolin-2-one Chemical compound CN1C(N(C2=C1C=NC=1C=CC(=CC2=1)C=1C=NC(=CC=1)C=1N=NN(C=1)C)[C@@H]1CNCC1)=O VUQNBJZDFINTTO-INIZCTEOSA-N 0.000 description 1
- NEUMHKLXEJULIE-UHFFFAOYSA-N 3-methyl-8-[6-(1-methyltriazol-4-yl)pyridin-3-yl]-1-piperidin-4-ylimidazo[4,5-c]quinolin-2-one Chemical compound CN1C(N(C2=C1C=NC=1C=CC(=CC2=1)C=1C=NC(=CC=1)C=1N=NN(C=1)C)C1CCNCC1)=O NEUMHKLXEJULIE-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- FTEQTVUZVCGVMK-UHFFFAOYSA-N 4-[(6-bromo-3-nitroquinolin-4-yl)amino]-1-methylcyclohexan-1-ol Chemical compound BrC=1C=C2C(=C(C=NC2=CC=1)[N+](=O)[O-])NC1CCC(CC1)(O)C FTEQTVUZVCGVMK-UHFFFAOYSA-N 0.000 description 1
- KUKASNZJTIKRMH-UHFFFAOYSA-N 4-amino-1-methylcyclohexan-1-ol Chemical compound CC1(O)CCC(N)CC1 KUKASNZJTIKRMH-UHFFFAOYSA-N 0.000 description 1
- DRNGLYHKYPNTEA-UHFFFAOYSA-N 4-azaniumylcyclohexane-1-carboxylate Chemical compound NC1CCC(C(O)=O)CC1 DRNGLYHKYPNTEA-UHFFFAOYSA-N 0.000 description 1
- ZLYBFBAHAQEEQQ-UHFFFAOYSA-N 4-chlorobenzenesulfonyl chloride Chemical compound ClC1=CC=C(S(Cl)(=O)=O)C=C1 ZLYBFBAHAQEEQQ-UHFFFAOYSA-N 0.000 description 1
- 125000004920 4-methyl-2-pentyl group Chemical group CC(CC(C)*)C 0.000 description 1
- NSPMIYGKQJPBQR-UHFFFAOYSA-N 4H-1,2,4-triazole Chemical compound C=1N=CNN=1 NSPMIYGKQJPBQR-UHFFFAOYSA-N 0.000 description 1
- JFBXMUZERCLCOR-UHFFFAOYSA-N 5-bromo-2-(1,2,4-triazol-1-yl)pyridine Chemical compound N1=CC(Br)=CC=C1N1N=CN=C1 JFBXMUZERCLCOR-UHFFFAOYSA-N 0.000 description 1
- PJFCISPDESNNAP-UHFFFAOYSA-N 5-bromo-2-(1-methyl-1,2,4-triazol-3-yl)pyridine Chemical compound CN1C=NC(C=2N=CC(Br)=CC=2)=N1 PJFCISPDESNNAP-UHFFFAOYSA-N 0.000 description 1
- ISCOXVDHAKWFHJ-UHFFFAOYSA-N 5-bromo-2-(1-methylpyrazol-3-yl)pyridine Chemical compound CN1C=CC(C=2N=CC(Br)=CC=2)=N1 ISCOXVDHAKWFHJ-UHFFFAOYSA-N 0.000 description 1
- KKJMVUNXOMLQNP-UHFFFAOYSA-N 5-bromo-2-(1-methyltriazol-4-yl)pyridine Chemical compound N1=NN(C)C=C1C1=CC=C(Br)C=N1 KKJMVUNXOMLQNP-UHFFFAOYSA-N 0.000 description 1
- FAUKVPVFFMMMBF-UHFFFAOYSA-N 5-bromo-2-(triazol-1-yl)pyridine Chemical compound N1=CC(Br)=CC=C1N1N=NC=C1 FAUKVPVFFMMMBF-UHFFFAOYSA-N 0.000 description 1
- HSNBRDZXJMPDGH-UHFFFAOYSA-N 5-bromo-2-iodopyridine Chemical compound BrC1=CC=C(I)N=C1 HSNBRDZXJMPDGH-UHFFFAOYSA-N 0.000 description 1
- KDOPAZIWBAHVJB-UHFFFAOYSA-N 5h-pyrrolo[3,2-d]pyrimidine Chemical compound C1=NC=C2NC=CC2=N1 KDOPAZIWBAHVJB-UHFFFAOYSA-N 0.000 description 1
- QAJYCQZQLVENRZ-UHFFFAOYSA-N 6-chloropyridin-3-amine Chemical compound NC1=CC=C(Cl)N=C1 QAJYCQZQLVENRZ-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- PPCGZUQGAHXEMF-UHFFFAOYSA-N 8-bromo-1-(4-hydroxy-4-methylcyclohexyl)-3-methylimidazo[4,5-c]quinolin-2-one Chemical compound BrC1=CC=2C3=C(C=NC=2C=C1)N(C(N3C1CCC(CC1)(O)C)=O)C PPCGZUQGAHXEMF-UHFFFAOYSA-N 0.000 description 1
- LKOWLRWTSOHASC-UHFFFAOYSA-N 8-bromo-1-(4-hydroxy-4-methylcyclohexyl)-3H-imidazo[4,5-c]quinolin-2-one Chemical compound BrC1=CC=2C3=C(C=NC=2C=C1)NC(N3C1CCC(CC1)(O)C)=O LKOWLRWTSOHASC-UHFFFAOYSA-N 0.000 description 1
- 101150011918 ATG13 gene Proteins 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 108010014380 Autophagy-Related Protein-1 Homolog Proteins 0.000 description 1
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- ZBZMEDDSIMMIBJ-UHFFFAOYSA-N BrC1=CC=2C3=C(C=NC=2C=C1)N(C(N3C1CN(C1)C(=O)OC(C)(C)C)=C=O)C Chemical compound BrC1=CC=2C3=C(C=NC=2C=C1)N(C(N3C1CN(C1)C(=O)OC(C)(C)C)=C=O)C ZBZMEDDSIMMIBJ-UHFFFAOYSA-N 0.000 description 1
- CWNFSSVIYQSSOC-UHFFFAOYSA-N BrC1=CC=2C3=C(C=NC=2C=C1)NC(N3C1CC2CCC(C1)N2C(=O)OC(C)(C)C)=C=O Chemical compound BrC1=CC=2C3=C(C=NC=2C=C1)NC(N3C1CC2CCC(C1)N2C(=O)OC(C)(C)C)=C=O CWNFSSVIYQSSOC-UHFFFAOYSA-N 0.000 description 1
- XUYTXFYXNCLVPE-UHFFFAOYSA-N BrC1=CC=2C3=C(C=NC=2C=C1)NC(N3C1CN(C1)C(=O)OC(C)(C)C)=C=O Chemical compound BrC1=CC=2C3=C(C=NC=2C=C1)NC(N3C1CN(C1)C(=O)OC(C)(C)C)=C=O XUYTXFYXNCLVPE-UHFFFAOYSA-N 0.000 description 1
- FDNFKZOXFOLLGE-GFCCVEGCSA-N BrC1=NC=2C3=C(C=NC=2C=C1)N(C(N3[C@H]1CN(CCC1)C(=O)OC(C)(C)C)=O)C Chemical compound BrC1=NC=2C3=C(C=NC=2C=C1)N(C(N3[C@H]1CN(CCC1)C(=O)OC(C)(C)C)=O)C FDNFKZOXFOLLGE-GFCCVEGCSA-N 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- WYFIPIZSOWRTDM-KJXWVISYSA-N CN1C(N(C2=C1C=NC=1C=CC(=CC2=1)C1CNC(CC1)C1=CC=CC=C1)[C@@H]1CN(CC1)C(=O)OC(C)(C)C)=O Chemical compound CN1C(N(C2=C1C=NC=1C=CC(=CC2=1)C1CNC(CC1)C1=CC=CC=C1)[C@@H]1CN(CC1)C(=O)OC(C)(C)C)=O WYFIPIZSOWRTDM-KJXWVISYSA-N 0.000 description 1
- BPUZINTWRCHYQU-SWCONJRYSA-N CN1C(N(C2=C1C=NC=1C=CC(=CC2=1)C1CNC(CC1)C=1C=NN(C=1)C)[C@@H]1CN(CC1)C(=O)OC(C)(C)C)=O Chemical compound CN1C(N(C2=C1C=NC=1C=CC(=CC2=1)C1CNC(CC1)C=1C=NN(C=1)C)[C@@H]1CN(CC1)C(=O)OC(C)(C)C)=O BPUZINTWRCHYQU-SWCONJRYSA-N 0.000 description 1
- BPUZINTWRCHYQU-YUVVGHDESA-N CN1C(N(C2=C1C=NC=1C=CC(=CC2=1)C1CNC(CC1)C=1C=NN(C=1)C)[C@H]1CN(CC1)C(=O)OC(C)(C)C)=O Chemical compound CN1C(N(C2=C1C=NC=1C=CC(=CC2=1)C1CNC(CC1)C=1C=NN(C=1)C)[C@H]1CN(CC1)C(=O)OC(C)(C)C)=O BPUZINTWRCHYQU-YUVVGHDESA-N 0.000 description 1
- WISZWXAUSGKAFJ-NRFANRHFSA-N CN1C(N(C2=C1C=NC=1C=CC(=CC2=1)C=1C=NC(=CC=1)C1=NN(C=C1)C)[C@@H]1CN(CC1)C(=O)OC(C)(C)C)=C=O Chemical compound CN1C(N(C2=C1C=NC=1C=CC(=CC2=1)C=1C=NC(=CC=1)C1=NN(C=C1)C)[C@@H]1CN(CC1)C(=O)OC(C)(C)C)=C=O WISZWXAUSGKAFJ-NRFANRHFSA-N 0.000 description 1
- OTHRHOSBVFNBCQ-UHFFFAOYSA-N CN1C(N(C2=C1C=NC=1C=CC(=CC2=1)C=1C=NC(=CC=1)C=1C=NN(C=1)C)C1CN(C1)C(=O)OC(C)(C)C)=C=O Chemical compound CN1C(N(C2=C1C=NC=1C=CC(=CC2=1)C=1C=NC(=CC=1)C=1C=NN(C=1)C)C1CN(C1)C(=O)OC(C)(C)C)=C=O OTHRHOSBVFNBCQ-UHFFFAOYSA-N 0.000 description 1
- HSJGYYRLOBTLEB-FQEVSTJZSA-N CN1C(N(C2=C1C=NC=1C=CC(=CC2=1)C=1C=NC(=CC=1)C=1N=NN(C=1)C)[C@@H]1CN(CC1)C(=O)OC(C)(C)C)=C=O Chemical compound CN1C(N(C2=C1C=NC=1C=CC(=CC2=1)C=1C=NC(=CC=1)C=1N=NN(C=1)C)[C@@H]1CN(CC1)C(=O)OC(C)(C)C)=C=O HSJGYYRLOBTLEB-FQEVSTJZSA-N 0.000 description 1
- QNFXKESUHFXIFE-OAQYLSRUSA-N CN1C(N(C2=C1C=NC=1C=CC(=CC2=1)C=1C=NC(=CC=1)C=1N=NN(C=1)C)[C@H]1CN(CCC1)C(=O)OC(C)(C)C)=C=O Chemical compound CN1C(N(C2=C1C=NC=1C=CC(=CC2=1)C=1C=NC(=CC=1)C=1N=NN(C=1)C)[C@H]1CN(CCC1)C(=O)OC(C)(C)C)=C=O QNFXKESUHFXIFE-OAQYLSRUSA-N 0.000 description 1
- ZDVVWNJIZDXXMQ-SFHVURJKSA-N CN1C(N(C2=C1C=NC=1C=CC(=NC2=1)C=1C=NC(=CC=1)C=1N=NN(C=1)C)[C@@H]1CN(CC1)C(=O)OC(C)(C)C)=C=O Chemical compound CN1C(N(C2=C1C=NC=1C=CC(=NC2=1)C=1C=NC(=CC=1)C=1N=NN(C=1)C)[C@@H]1CN(CC1)C(=O)OC(C)(C)C)=C=O ZDVVWNJIZDXXMQ-SFHVURJKSA-N 0.000 description 1
- CAGNPQWMQCJWQE-UHFFFAOYSA-N CN1N=CC(=C1)C1=CC=C(C=N1)C1=CC=2C3=C(C=NC=2C=C1)N(C(N3C1CC2CCC(C1)N2C(=O)OC(C)(C)C)=C=O)C Chemical compound CN1N=CC(=C1)C1=CC=C(C=N1)C1=CC=2C3=C(C=NC=2C=C1)N(C(N3C1CC2CCC(C1)N2C(=O)OC(C)(C)C)=C=O)C CAGNPQWMQCJWQE-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 102100029816 DEP domain-containing mTOR-interacting protein Human genes 0.000 description 1
- 208000001380 Diabetic Ketoacidosis Diseases 0.000 description 1
- 102100031250 Disks large-associated protein 1 Human genes 0.000 description 1
- 102000001301 EGF receptor Human genes 0.000 description 1
- 108060006698 EGF receptor Proteins 0.000 description 1
- 102100030013 Endoribonuclease Human genes 0.000 description 1
- 101710199605 Endoribonuclease Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241001125671 Eretmochelys imbricata Species 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- 206010051066 Gastrointestinal stromal tumour Diseases 0.000 description 1
- 208000021309 Germ cell tumor Diseases 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 102000009465 Growth Factor Receptors Human genes 0.000 description 1
- 108010009202 Growth Factor Receptors Proteins 0.000 description 1
- 239000007821 HATU Substances 0.000 description 1
- 241001272567 Hominoidea Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000865183 Homo sapiens DEP domain-containing mTOR-interacting protein Proteins 0.000 description 1
- 101000731000 Homo sapiens Membrane-associated progesterone receptor component 1 Proteins 0.000 description 1
- 101000690268 Homo sapiens Proline-rich AKT1 substrate 1 Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 102100022875 Hypoxia-inducible factor 1-alpha Human genes 0.000 description 1
- 108050009527 Hypoxia-inducible factor-1 alpha Proteins 0.000 description 1
- WRYCSMQKUKOKBP-UHFFFAOYSA-N Imidazolidine Chemical compound C1CNCN1 WRYCSMQKUKOKBP-UHFFFAOYSA-N 0.000 description 1
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 102000046985 LST8 Homolog mTOR Associated Human genes 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 101150018665 MAPK3 gene Proteins 0.000 description 1
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 1
- 229910021380 Manganese Chloride Inorganic materials 0.000 description 1
- GLFNIEUTAYBVOC-UHFFFAOYSA-L Manganese chloride Chemical compound Cl[Mn]Cl GLFNIEUTAYBVOC-UHFFFAOYSA-L 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 102000007474 Multiprotein Complexes Human genes 0.000 description 1
- 108010085220 Multiprotein Complexes Proteins 0.000 description 1
- 101100087591 Mus musculus Rictor gene Proteins 0.000 description 1
- TZYWCYJVHRLUCT-VABKMULXSA-N N-benzyloxycarbonyl-L-leucyl-L-leucyl-L-leucinal Chemical compound CC(C)C[C@@H](C=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)OCC1=CC=CC=C1 TZYWCYJVHRLUCT-VABKMULXSA-N 0.000 description 1
- UQFQONCQIQEYPJ-UHFFFAOYSA-N N-methylpyrazole Chemical compound CN1C=CC=N1 UQFQONCQIQEYPJ-UHFFFAOYSA-N 0.000 description 1
- MWXFFUFPCGHVDN-NRFANRHFSA-N N1(N=CC=C1)C1=CC=C(C=N1)C1=CC=2C3=C(C=NC=2C=C1)N(C(N3[C@@H]1CN(CC1)C(=O)OC(C)(C)C)=C=O)C Chemical compound N1(N=CC=C1)C1=CC=C(C=N1)C1=CC=2C3=C(C=NC=2C=C1)N(C(N3[C@@H]1CN(CC1)C(=O)OC(C)(C)C)=C=O)C MWXFFUFPCGHVDN-NRFANRHFSA-N 0.000 description 1
- 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 description 1
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- WYNCHZVNFNFDNH-UHFFFAOYSA-N Oxazolidine Chemical compound C1COCN1 WYNCHZVNFNFDNH-UHFFFAOYSA-N 0.000 description 1
- 108010011536 PTEN Phosphohydrolase Proteins 0.000 description 1
- 102000014160 PTEN Phosphohydrolase Human genes 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 102100024091 Proline-rich AKT1 substrate 1 Human genes 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 108010029031 Regulatory-Associated Protein of mTOR Proteins 0.000 description 1
- 102100040969 Regulatory-associated protein of mTOR Human genes 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 102100024908 Ribosomal protein S6 kinase beta-1 Human genes 0.000 description 1
- 101710108924 Ribosomal protein S6 kinase beta-1 Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 101150040067 STK11 gene Proteins 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 101710113029 Serine/threonine-protein kinase Proteins 0.000 description 1
- 102100039988 Serine/threonine-protein kinase ULK1 Human genes 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 102000013275 Somatomedins Human genes 0.000 description 1
- 241000862969 Stella Species 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 101710115678 Target of rapamycin complex subunit LST8 Proteins 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 108700025716 Tumor Suppressor Genes Proteins 0.000 description 1
- 102000044209 Tumor Suppressor Genes Human genes 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- 208000010011 Vitamin A Deficiency Diseases 0.000 description 1
- 206010047623 Vitamin C deficiency Diseases 0.000 description 1
- 206010047626 Vitamin D Deficiency Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 150000008043 acidic salts Chemical class 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 238000012382 advanced drug delivery Methods 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- 125000005011 alkyl ether group Chemical group 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 125000005428 anthryl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C3C(*)=C([H])C([H])=C([H])C3=C([H])C2=C1[H] 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000011319 anticancer therapy Methods 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 125000002029 aromatic hydrocarbon group Chemical group 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 125000003828 azulenyl group Chemical group 0.000 description 1
- 239000007640 basal medium Substances 0.000 description 1
- RFRXIWQYSOIBDI-UHFFFAOYSA-N benzarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC=C(O)C=C1 RFRXIWQYSOIBDI-UHFFFAOYSA-N 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- XJHABGPPCLHLLV-UHFFFAOYSA-N benzo[de]isoquinoline-1,3-dione Chemical compound C1=CC(C(=O)NC2=O)=C3C2=CC=CC3=C1 XJHABGPPCLHLLV-UHFFFAOYSA-N 0.000 description 1
- BNBQRQQYDMDJAH-UHFFFAOYSA-N benzodioxan Chemical compound C1=CC=C2OCCOC2=C1 BNBQRQQYDMDJAH-UHFFFAOYSA-N 0.000 description 1
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- 125000002618 bicyclic heterocycle group Chemical group 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 125000005998 bromoethyl group Chemical group 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229910052792 caesium Inorganic materials 0.000 description 1
- TVFDJXOCXUVLDH-UHFFFAOYSA-N caesium atom Chemical compound [Cs] TVFDJXOCXUVLDH-UHFFFAOYSA-N 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000004709 cell invasion Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 230000004637 cellular stress Effects 0.000 description 1
- 230000006364 cellular survival Effects 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- OGEBRHQLRGFBNV-RZDIXWSQSA-N chembl2036808 Chemical compound C12=NC(NCCCC)=NC=C2C(C=2C=CC(F)=CC=2)=NN1C[C@H]1CC[C@H](N)CC1 OGEBRHQLRGFBNV-RZDIXWSQSA-N 0.000 description 1
- 210000001136 chorion Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000001360 collision-induced dissociation Methods 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000013066 combination product Substances 0.000 description 1
- 229940127555 combination product Drugs 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- VZFUCHSFHOYXIS-UHFFFAOYSA-N cycloheptane carboxylic acid Natural products OC(=O)C1CCCCCC1 VZFUCHSFHOYXIS-UHFFFAOYSA-N 0.000 description 1
- 125000002188 cycloheptatrienyl group Chemical group C1(=CC=CC=CC1)* 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000003678 cyclohexadienyl group Chemical group C1(=CC=CCC1)* 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- PFWWSGFPICCWGU-UHFFFAOYSA-N cyclopropanesulfonyl chloride Chemical compound ClS(=O)(=O)C1CC1 PFWWSGFPICCWGU-UHFFFAOYSA-N 0.000 description 1
- 210000004292 cytoskeleton Anatomy 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 239000008380 degradant Substances 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 125000002576 diazepinyl group Chemical group N1N=C(C=CC=C1)* 0.000 description 1
- 239000002027 dichloromethane extract Substances 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- 125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 description 1
- 125000005043 dihydropyranyl group Chemical group O1C(CCC=C1)* 0.000 description 1
- 125000005057 dihydrothienyl group Chemical group S1C(CC=C1)* 0.000 description 1
- 239000013024 dilution buffer Substances 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 125000005411 dithiolanyl group Chemical group S1SC(CC1)* 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 230000009189 diving Effects 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000007905 drug manufacturing Methods 0.000 description 1
- 230000002183 duodenal effect Effects 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- DBLXOVFQHHSKRC-UHFFFAOYSA-N ethanesulfonic acid;2-piperazin-1-ylethanol Chemical compound CCS(O)(=O)=O.OCCN1CCNCC1 DBLXOVFQHHSKRC-UHFFFAOYSA-N 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- VFRSADQPWYCXDG-LEUCUCNGSA-N ethyl (2s,5s)-5-methylpyrrolidine-2-carboxylate;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.CCOC(=O)[C@@H]1CC[C@H](C)N1 VFRSADQPWYCXDG-LEUCUCNGSA-N 0.000 description 1
- WUDNUHPRLBTKOJ-UHFFFAOYSA-N ethyl isocyanate Chemical compound CCN=C=O WUDNUHPRLBTKOJ-UHFFFAOYSA-N 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000007185 extracellular pathway Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 description 1
- 229960004884 fluconazole Drugs 0.000 description 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 125000000262 haloalkenyl group Chemical group 0.000 description 1
- 125000000232 haloalkynyl group Chemical group 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- KJDJPXUIZYHXEZ-UHFFFAOYSA-N hydrogen sulfate;methylaminoazanium Chemical compound CN[NH3+].OS([O-])(=O)=O KJDJPXUIZYHXEZ-UHFFFAOYSA-N 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000006662 intracellular pathway Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- HVTICUPFWKNHNG-UHFFFAOYSA-N iodoethane Chemical compound CCI HVTICUPFWKNHNG-UHFFFAOYSA-N 0.000 description 1
- INQOMBQAUSQDDS-BJUDXGSMSA-N iodomethane Chemical class I[11CH3] INQOMBQAUSQDDS-BJUDXGSMSA-N 0.000 description 1
- 125000002510 isobutoxy group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])O* 0.000 description 1
- 125000000555 isopropenyl group Chemical group [H]\C([H])=C(\*)C([H])([H])[H] 0.000 description 1
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- ZLTPDFXIESTBQG-UHFFFAOYSA-N isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- NXPHGHWWQRMDIA-UHFFFAOYSA-M magnesium;carbanide;bromide Chemical compound [CH3-].[Mg+2].[Br-] NXPHGHWWQRMDIA-UHFFFAOYSA-M 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000011565 manganese chloride Substances 0.000 description 1
- 235000002867 manganese chloride Nutrition 0.000 description 1
- 229940099607 manganese chloride Drugs 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 201000006512 mast cell neoplasm Diseases 0.000 description 1
- 208000006971 mastocytoma Diseases 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 210000004088 microvessel Anatomy 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 125000006606 n-butoxy group Chemical group 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003506 n-propoxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000015286 negative regulation of phagocytosis Effects 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 210000005170 neoplastic cell Anatomy 0.000 description 1
- LYGJENNIWJXYER-UHFFFAOYSA-N nitromethane Chemical compound C[N+]([O-])=O LYGJENNIWJXYER-UHFFFAOYSA-N 0.000 description 1
- 125000006574 non-aromatic ring group Chemical group 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 238000001668 nucleic acid synthesis Methods 0.000 description 1
- 208000030212 nutrition disease Diseases 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000002246 oncogenic effect Effects 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 125000005561 phenanthryl group Chemical group 0.000 description 1
- 125000001791 phenazinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3N=C12)* 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- XKJCHHZQLQNZHY-UHFFFAOYSA-N phthalimide Chemical compound C1=CC=C2C(=O)NC(=O)C2=C1 XKJCHHZQLQNZHY-UHFFFAOYSA-N 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 125000004483 piperidin-3-yl group Chemical group N1CC(CCC1)* 0.000 description 1
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 239000004323 potassium nitrate Substances 0.000 description 1
- 235000010333 potassium nitrate Nutrition 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- USPWKWBDZOARPV-UHFFFAOYSA-N pyrazolidine Chemical compound C1CNNC1 USPWKWBDZOARPV-UHFFFAOYSA-N 0.000 description 1
- PBMFSQRYOILNGV-UHFFFAOYSA-N pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- UTOMICFLROGMAE-UHFFFAOYSA-N quinoline-3,4-diamine Chemical compound C1=CC=CC2=C(N)C(N)=CN=C21 UTOMICFLROGMAE-UHFFFAOYSA-N 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 208000010233 scurvy Diseases 0.000 description 1
- 125000005920 sec-butoxy group Chemical group 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 229960002930 sirolimus Drugs 0.000 description 1
- 150000003385 sodium Chemical class 0.000 description 1
- 238000007614 solvation Methods 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- VNFWTIYUKDMAOP-UHFFFAOYSA-N sphos Chemical compound COC1=CC=CC(OC)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 VNFWTIYUKDMAOP-UHFFFAOYSA-N 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 235000011150 stannous chloride Nutrition 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 125000003107 substituted aryl group Chemical group 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- WFJDTIJYIWZSRY-LLVKDONJSA-N tert-butyl (3R)-3-(8-chloro-2-oxo-3H-imidazo[4,5-c][1,5]naphthyridin-1-yl)piperidine-1-carboxylate Chemical compound ClC1=NC=2C3=C(C=NC=2C=C1)NC(N3[C@H]1CN(CCC1)C(=O)OC(C)(C)C)=O WFJDTIJYIWZSRY-LLVKDONJSA-N 0.000 description 1
- CBVFHTSRCCDINI-CYBMUJFWSA-N tert-butyl (3R)-3-[(3-amino-6-bromoquinolin-4-yl)amino]piperidine-1-carboxylate Chemical compound NC=1C=NC2=CC=C(C=C2C=1N[C@H]1CN(CCC1)C(=O)OC(C)(C)C)Br CBVFHTSRCCDINI-CYBMUJFWSA-N 0.000 description 1
- JJLDZENFWLYESM-GFCCVEGCSA-N tert-butyl (3R)-3-[(3-amino-6-bromoquinolin-4-yl)amino]pyrrolidine-1-carboxylate Chemical compound NC=1C=NC2=CC=C(C=C2C=1N[C@H]1CN(CC1)C(=O)OC(C)(C)C)Br JJLDZENFWLYESM-GFCCVEGCSA-N 0.000 description 1
- IOBAIJWUPLAWBM-CYBMUJFWSA-N tert-butyl (3R)-3-[(6-bromo-3-nitroquinolin-4-yl)amino]piperidine-1-carboxylate Chemical compound BrC=1C=C2C(=C(C=NC2=CC=1)[N+](=O)[O-])N[C@H]1CN(CCC1)C(=O)OC(C)(C)C IOBAIJWUPLAWBM-CYBMUJFWSA-N 0.000 description 1
- VWUBKAUJVSEVER-GFCCVEGCSA-N tert-butyl (3R)-3-[(6-bromo-3-nitroquinolin-4-yl)amino]pyrrolidine-1-carboxylate Chemical compound BrC=1C=C2C(=C(C=NC2=CC=1)[N+](=O)[O-])N[C@H]1CN(CC1)C(=O)OC(C)(C)C VWUBKAUJVSEVER-GFCCVEGCSA-N 0.000 description 1
- KYCXZAXOWKFWKI-LLVKDONJSA-N tert-butyl (3R)-3-[(6-chloro-3-nitro-1,5-naphthyridin-4-yl)amino]piperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC[C@H](C1)NC1=C2N=C(Cl)C=CC2=NC=C1[N+]([O-])=O KYCXZAXOWKFWKI-LLVKDONJSA-N 0.000 description 1
- LKZWQXYAESJTFO-HXUWFJFHSA-N tert-butyl (3R)-3-[3-methyl-8-[6-(1-methylpyrazol-4-yl)pyridin-3-yl]-2-oxoimidazo[4,5-c][1,5]naphthyridin-1-yl]piperidine-1-carboxylate Chemical compound CN1C(N(C2=C1C=NC=1C=CC(=NC2=1)C=1C=NC(=CC=1)C=1C=NN(C=1)C)[C@H]1CN(CCC1)C(=O)OC(C)(C)C)=O LKZWQXYAESJTFO-HXUWFJFHSA-N 0.000 description 1
- JBPHXWBIPYXIEU-JOCHJYFZSA-N tert-butyl (3R)-3-[3-methyl-8-[6-(1-methylpyrazol-4-yl)pyridin-3-yl]-2-oxoimidazo[4,5-c]quinolin-1-yl]piperidine-1-carboxylate Chemical compound CN1C(N(C2=C1C=NC=1C=CC(=CC2=1)C=1C=NC(=CC=1)C=1C=NN(C=1)C)[C@H]1CN(CCC1)C(=O)OC(C)(C)C)=O JBPHXWBIPYXIEU-JOCHJYFZSA-N 0.000 description 1
- GSILANSIEBYHAA-JTQLQIEISA-N tert-butyl (3S)-3-(8-chloro-2-oxo-3H-imidazo[4,5-c][1,5]naphthyridin-1-yl)pyrrolidine-1-carboxylate Chemical compound ClC1=NC=2C3=C(C=NC=2C=C1)NC(N3[C@@H]1CN(CC1)C(=O)OC(C)(C)C)=O GSILANSIEBYHAA-JTQLQIEISA-N 0.000 description 1
- PBLHVPSEZGJEFA-NSHDSACASA-N tert-butyl (3S)-3-(8-chloro-3-methyl-2-oxoimidazo[4,5-c][1,5]naphthyridin-1-yl)pyrrolidine-1-carboxylate Chemical compound ClC1=NC=2C3=C(C=NC=2C=C1)N(C(N3[C@@H]1CN(CC1)C(=O)OC(C)(C)C)=O)C PBLHVPSEZGJEFA-NSHDSACASA-N 0.000 description 1
- JJLDZENFWLYESM-LBPRGKRZSA-N tert-butyl (3S)-3-[(3-amino-6-bromoquinolin-4-yl)amino]pyrrolidine-1-carboxylate Chemical compound NC=1C=NC2=CC=C(C=C2C=1N[C@@H]1CN(CC1)C(=O)OC(C)(C)C)Br JJLDZENFWLYESM-LBPRGKRZSA-N 0.000 description 1
- ASJOXFLOVZTWON-JTQLQIEISA-N tert-butyl (3S)-3-[(3-amino-6-chloro-1,5-naphthyridin-4-yl)amino]pyrrolidine-1-carboxylate Chemical compound NC=1C=NC2=CC=C(N=C2C=1N[C@@H]1CN(CC1)C(=O)OC(C)(C)C)Cl ASJOXFLOVZTWON-JTQLQIEISA-N 0.000 description 1
- VWUBKAUJVSEVER-LBPRGKRZSA-N tert-butyl (3S)-3-[(6-bromo-3-nitroquinolin-4-yl)amino]pyrrolidine-1-carboxylate Chemical compound BrC=1C=C2C(=C(C=NC2=CC=1)[N+](=O)[O-])N[C@@H]1CN(CC1)C(=O)OC(C)(C)C VWUBKAUJVSEVER-LBPRGKRZSA-N 0.000 description 1
- DGHHBIKHYOEXAN-JTQLQIEISA-N tert-butyl (3S)-3-[(6-chloro-3-nitro-1,5-naphthyridin-4-yl)amino]pyrrolidine-1-carboxylate Chemical compound ClC=1N=C2C(=C(C=NC2=CC=1)[N+](=O)[O-])N[C@@H]1CN(CC1)C(=O)OC(C)(C)C DGHHBIKHYOEXAN-JTQLQIEISA-N 0.000 description 1
- QHPOSFITXTVLIU-NRFANRHFSA-N tert-butyl (3S)-3-[3-methyl-2-oxo-8-(6-phenylpyridin-3-yl)imidazo[4,5-c][1,5]naphthyridin-1-yl]pyrrolidine-1-carboxylate Chemical compound CN1C(N(C2=C1C=NC=1C=CC(=NC2=1)C=1C=NC(=CC=1)C1=CC=CC=C1)[C@@H]1CN(CC1)C(=O)OC(C)(C)C)=O QHPOSFITXTVLIU-NRFANRHFSA-N 0.000 description 1
- LGRGQUVMWKXFTI-IBGZPJMESA-N tert-butyl (3S)-3-[3-methyl-8-[6-(1-methylpyrazol-4-yl)pyridin-3-yl]-2-oxoimidazo[4,5-c][1,5]naphthyridin-1-yl]pyrrolidine-1-carboxylate Chemical compound CN1C(N(C2=C1C=NC=1C=CC(=NC2=1)C=1C=NC(=CC=1)C=1C=NN(C=1)C)[C@@H]1CN(CC1)C(=O)OC(C)(C)C)=O LGRGQUVMWKXFTI-IBGZPJMESA-N 0.000 description 1
- AKQXKEBCONUWCL-MRVPVSSYSA-N tert-butyl (3r)-3-aminopiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC[C@@H](N)C1 AKQXKEBCONUWCL-MRVPVSSYSA-N 0.000 description 1
- OTBNAMPLYXLHMG-UHFFFAOYSA-N tert-butyl 3-(8-bromo-2-oxo-3H-imidazo[4,5-c]quinolin-1-yl)piperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCCC(C1)N1C(=O)NC2=C1C1=CC(Br)=CC=C1N=C2 OTBNAMPLYXLHMG-UHFFFAOYSA-N 0.000 description 1
- BGRVCJHTROMQRN-UHFFFAOYSA-N tert-butyl 3-(8-bromo-2-oxo-3H-imidazo[4,5-c]quinolin-1-yl)pyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(C1)N1C(=O)NC2=C1C1=CC(Br)=CC=C1N=C2 BGRVCJHTROMQRN-UHFFFAOYSA-N 0.000 description 1
- FDNFKZOXFOLLGE-UHFFFAOYSA-N tert-butyl 3-(8-bromo-3-methyl-2-oxoimidazo[4,5-c][1,5]naphthyridin-1-yl)piperidine-1-carboxylate Chemical compound BrC1=NC=2C3=C(C=NC=2C=C1)N(C(N3C1CN(CCC1)C(=O)OC(C)(C)C)=O)C FDNFKZOXFOLLGE-UHFFFAOYSA-N 0.000 description 1
- WFJDTIJYIWZSRY-UHFFFAOYSA-N tert-butyl 3-(8-chloro-2-oxo-3H-imidazo[4,5-c][1,5]naphthyridin-1-yl)piperidine-1-carboxylate Chemical compound ClC1=NC=2C3=C(C=NC=2C=C1)NC(N3C1CN(CCC1)C(=O)OC(C)(C)C)=O WFJDTIJYIWZSRY-UHFFFAOYSA-N 0.000 description 1
- OBKUHZYPUZHXIG-UHFFFAOYSA-N tert-butyl 3-[(3-amino-6-bromoquinolin-4-yl)amino]-8-azabicyclo[3.2.1]octane-8-carboxylate Chemical compound BrC=1C=C2C(=C(C=NC2=CC=1)N)NC1CC2CCC(C1)N2C(=O)OC(C)(C)C OBKUHZYPUZHXIG-UHFFFAOYSA-N 0.000 description 1
- YWECYDGMZVYZFA-UHFFFAOYSA-N tert-butyl 3-[(3-amino-6-bromoquinolin-4-yl)amino]azetidine-1-carboxylate Chemical compound BrC=1C=C2C(=C(C=NC2=CC=1)N)NC1CN(C1)C(=O)OC(C)(C)C YWECYDGMZVYZFA-UHFFFAOYSA-N 0.000 description 1
- CBVFHTSRCCDINI-UHFFFAOYSA-N tert-butyl 3-[(3-amino-6-bromoquinolin-4-yl)amino]piperidine-1-carboxylate Chemical compound C1(=CC=C2C(C(NC3CCCN(C3)C(=O)OC(C)(C)C)=C(N)C=N2)=C1)Br CBVFHTSRCCDINI-UHFFFAOYSA-N 0.000 description 1
- JJLDZENFWLYESM-UHFFFAOYSA-N tert-butyl 3-[(3-amino-6-bromoquinolin-4-yl)amino]pyrrolidine-1-carboxylate Chemical compound NC=1C=NC2=CC=C(C=C2C=1NC1CN(CC1)C(=O)OC(C)(C)C)Br JJLDZENFWLYESM-UHFFFAOYSA-N 0.000 description 1
- MCAOERCBQAGPLP-UHFFFAOYSA-N tert-butyl 3-[(3-amino-6-chloro-1,5-naphthyridin-4-yl)amino]piperidine-1-carboxylate Chemical compound NC=1C=NC2=CC=C(N=C2C=1NC1CN(CCC1)C(=O)OC(C)(C)C)Cl MCAOERCBQAGPLP-UHFFFAOYSA-N 0.000 description 1
- UFDCSFCPTHCVPK-UHFFFAOYSA-N tert-butyl 3-[(6-bromo-3-nitroquinolin-4-yl)amino]azetidine-1-carboxylate Chemical compound BrC=1C=C2C(=C(C=NC2=CC=1)[N+](=O)[O-])NC1CN(C1)C(=O)OC(C)(C)C UFDCSFCPTHCVPK-UHFFFAOYSA-N 0.000 description 1
- IOBAIJWUPLAWBM-UHFFFAOYSA-N tert-butyl 3-[(6-bromo-3-nitroquinolin-4-yl)amino]piperidine-1-carboxylate Chemical compound BrC=1C=C2C(=C(C=NC2=CC=1)[N+](=O)[O-])NC1CN(CCC1)C(=O)OC(C)(C)C IOBAIJWUPLAWBM-UHFFFAOYSA-N 0.000 description 1
- VWUBKAUJVSEVER-UHFFFAOYSA-N tert-butyl 3-[(6-bromo-3-nitroquinolin-4-yl)amino]pyrrolidine-1-carboxylate Chemical compound BrC=1C=C2C(=C(C=NC2=CC=1)[N+](=O)[O-])NC1CN(CC1)C(=O)OC(C)(C)C VWUBKAUJVSEVER-UHFFFAOYSA-N 0.000 description 1
- KYCXZAXOWKFWKI-UHFFFAOYSA-N tert-butyl 3-[(6-chloro-3-nitro-1,5-naphthyridin-4-yl)amino]piperidine-1-carboxylate Chemical compound ClC=1N=C2C(=C(C=NC2=CC=1)[N+](=O)[O-])NC1CN(CCC1)C(=O)OC(C)(C)C KYCXZAXOWKFWKI-UHFFFAOYSA-N 0.000 description 1
- BPUZINTWRCHYQU-UHFFFAOYSA-N tert-butyl 3-[3-methyl-8-[6-(1-methylpyrazol-4-yl)piperidin-3-yl]-2-oxoimidazo[4,5-c]quinolin-1-yl]pyrrolidine-1-carboxylate Chemical compound CN1C(N(C2=C1C=NC=1C=CC(=CC2=1)C1CNC(CC1)C=1C=NN(C=1)C)C1CN(CC1)C(=O)OC(C)(C)C)=O BPUZINTWRCHYQU-UHFFFAOYSA-N 0.000 description 1
- LKZWQXYAESJTFO-UHFFFAOYSA-N tert-butyl 3-[3-methyl-8-[6-(1-methylpyrazol-4-yl)pyridin-3-yl]-2-oxoimidazo[4,5-c][1,5]naphthyridin-1-yl]piperidine-1-carboxylate Chemical compound CN1C(N(C2=C1C=NC=1C=CC(=NC2=1)C=1C=NC(=CC=1)C=1C=NN(C=1)C)C1CN(CCC1)C(=O)OC(C)(C)C)=O LKZWQXYAESJTFO-UHFFFAOYSA-N 0.000 description 1
- CUNWOWNMIPNXJM-UHFFFAOYSA-N tert-butyl 3-[3-methyl-8-[6-(1-methyltriazol-4-yl)pyridin-3-yl]-2-oxoimidazo[4,5-c]quinolin-1-yl]-8-azabicyclo[3.2.1]octane-8-carboxylate Chemical compound CN1N=NC(=C1)C1=CC=C(C=N1)C1=CC=2C3=C(C=NC=2C=C1)N(C(N3C1CC2CCC(C1)N2C(=O)OC(C)(C)C)=O)C CUNWOWNMIPNXJM-UHFFFAOYSA-N 0.000 description 1
- NZJKEPNCNBWESN-UHFFFAOYSA-N tert-butyl 3-amino-8-azabicyclo[3.2.1]octane-8-carboxylate Chemical compound C1C(N)CC2CCC1N2C(=O)OC(C)(C)C NZJKEPNCNBWESN-UHFFFAOYSA-N 0.000 description 1
- WPGLRFGDZJSQGI-UHFFFAOYSA-N tert-butyl 3-aminoazetidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CC(N)C1 WPGLRFGDZJSQGI-UHFFFAOYSA-N 0.000 description 1
- AKQXKEBCONUWCL-UHFFFAOYSA-N tert-butyl 3-aminopiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCCC(N)C1 AKQXKEBCONUWCL-UHFFFAOYSA-N 0.000 description 1
- JIAISGAPIFJMFX-UHFFFAOYSA-N tert-butyl 4-(8-bromo-2-oxo-3H-imidazo[4,5-c]quinolin-1-yl)piperidine-1-carboxylate Chemical compound BrC1=CC=2C3=C(C=NC=2C=C1)NC(N3C1CCN(CC1)C(=O)OC(C)(C)C)=O JIAISGAPIFJMFX-UHFFFAOYSA-N 0.000 description 1
- HGWBDGYCHBOWLS-UHFFFAOYSA-N tert-butyl 4-[(3-amino-6-bromoquinolin-4-yl)amino]piperidine-1-carboxylate Chemical compound NC=1C=NC2=CC=C(C=C2C=1NC1CCN(CC1)C(=O)OC(C)(C)C)Br HGWBDGYCHBOWLS-UHFFFAOYSA-N 0.000 description 1
- ZPFITKUYPKSACJ-UHFFFAOYSA-N tert-butyl 4-[(6-bromo-3-nitroquinolin-4-yl)amino]piperidine-1-carboxylate Chemical compound BrC=1C=C2C(=C(C=NC2=CC=1)[N+](=O)[O-])NC1CCN(CC1)C(=O)OC(C)(C)C ZPFITKUYPKSACJ-UHFFFAOYSA-N 0.000 description 1
- QUIKDESLFBHSJI-UHFFFAOYSA-N tert-butyl 4-[3-methyl-8-[6-(1-methylpyrazol-4-yl)pyridin-3-yl]-2-oxoimidazo[4,5-c]quinolin-1-yl]piperidine-1-carboxylate Chemical compound CN1C(N(C2=C1C=NC=1C=CC(=CC2=1)C=1C=NC(=CC=1)C=1C=NN(C=1)C)C1CCN(CC1)C(=O)OC(C)(C)C)=O QUIKDESLFBHSJI-UHFFFAOYSA-N 0.000 description 1
- MQJNEKKJIGZRQN-UHFFFAOYSA-N tert-butyl 4-[3-methyl-8-[6-(1-methyltriazol-4-yl)pyridin-3-yl]-2-oxoimidazo[4,5-c]quinolin-1-yl]piperidine-1-carboxylate Chemical compound CN1C(N(C2=C1C=NC=1C=CC(=CC2=1)C=1C=NC(=CC=1)C=1N=NN(C=1)C)C1CCN(CC1)C(=O)OC(C)(C)C)=O MQJNEKKJIGZRQN-UHFFFAOYSA-N 0.000 description 1
- LZRDHSFPLUWYAX-UHFFFAOYSA-N tert-butyl 4-aminopiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(N)CC1 LZRDHSFPLUWYAX-UHFFFAOYSA-N 0.000 description 1
- XBQDFJJEMHAHEI-UHFFFAOYSA-N tert-butyl N-[2-(8-bromo-2-oxo-3H-imidazo[4,5-c]quinolin-1-yl)ethyl]carbamate Chemical compound BrC1=CC=2C3=C(C=NC=2C=C1)NC(N3CCNC(OC(C)(C)C)=O)=O XBQDFJJEMHAHEI-UHFFFAOYSA-N 0.000 description 1
- BFOGGGXIHCJDDZ-UHFFFAOYSA-N tert-butyl N-[2-(8-bromo-3-methyl-2-oxoimidazo[4,5-c]quinolin-1-yl)ethyl]carbamate Chemical compound BrC1=CC=2C3=C(C=NC=2C=C1)N(C(N3CCNC(OC(C)(C)C)=O)=O)C BFOGGGXIHCJDDZ-UHFFFAOYSA-N 0.000 description 1
- YPCMEDWZDMJXFM-UHFFFAOYSA-N tert-butyl N-[2-[(3-amino-6-bromoquinolin-4-yl)amino]ethyl]carbamate Chemical compound NC=1C=NC2=CC=C(C=C2C=1NCCNC(OC(C)(C)C)=O)Br YPCMEDWZDMJXFM-UHFFFAOYSA-N 0.000 description 1
- JREJRAMRLLGRPL-UHFFFAOYSA-N tert-butyl N-[2-[(6-bromo-3-nitroquinolin-4-yl)amino]ethyl]carbamate Chemical compound BrC=1C=C2C(=C(C=NC2=CC=1)[N+](=O)[O-])NCCNC(OC(C)(C)C)=O JREJRAMRLLGRPL-UHFFFAOYSA-N 0.000 description 1
- JFSFSPACXABHJB-UHFFFAOYSA-N tert-butyl N-[2-[3-methyl-8-[6-(1-methylpyrazol-4-yl)pyridin-3-yl]-2-oxoimidazo[4,5-c]quinolin-1-yl]ethyl]carbamate Chemical compound CN1C(N(C2=C1C=NC=1C=CC(=CC2=1)C=1C=NC(=CC=1)C=1C=NN(C=1)C)CCNC(OC(C)(C)C)=O)=O JFSFSPACXABHJB-UHFFFAOYSA-N 0.000 description 1
- DZKXFTPOGGFHOX-UHFFFAOYSA-N tert-butyl n-(4-hydroxy-4-methylcyclohexyl)carbamate Chemical compound CC(C)(C)OC(=O)NC1CCC(C)(O)CC1 DZKXFTPOGGFHOX-UHFFFAOYSA-N 0.000 description 1
- OEQJOYQHIGIVTN-UHFFFAOYSA-N tert-butyl nonanoate Chemical compound CCCCCCCCC(=O)OC(C)(C)C OEQJOYQHIGIVTN-UHFFFAOYSA-N 0.000 description 1
- BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 1
- 125000001973 tert-pentyl group Chemical group [H]C([H])([H])C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- RAOIDOHSFRTOEL-UHFFFAOYSA-N tetrahydrothiophene Chemical compound C1CCSC1 RAOIDOHSFRTOEL-UHFFFAOYSA-N 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000005308 thiazepinyl group Chemical group S1N=C(C=CC=C1)* 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 125000002053 thietanyl group Chemical group 0.000 description 1
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- 229910052718 tin Inorganic materials 0.000 description 1
- 239000011135 tin Substances 0.000 description 1
- AXZWODMDQAVCJE-UHFFFAOYSA-L tin(II) chloride (anhydrous) Chemical compound [Cl-].[Cl-].[Sn+2] AXZWODMDQAVCJE-UHFFFAOYSA-L 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 230000004565 tumor cell growth Effects 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical class C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 238000003828 vacuum filtration Methods 0.000 description 1
- 206010046885 vaginal cancer Diseases 0.000 description 1
- 208000013139 vaginal neoplasm Diseases 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Description
H、
任意にハロゲン、シアノ基、アミノ基、ヒドロキシ基、カルボキシル基、トリフルオロメチル基、及び単環式又は二環式アリール基から選択される少なくとも1つの基に置換されたC1−6のアルキル基、C1−6のアルコキシ基、C2−6のアルケニル基、又はC2−6のアルキニル基から選択され、
又は、
R6CO、R6SO2、R6SO(その中、R6はNH2、NHR7、任意にヒドロキシ基、メルカプト基、アミノ基、トリフルオロメチル基及びハロゲンの少なくとも1つに置換されたC1−6のアルキル基、C1−6のアルコキシ基、C2−6のアルケニル基、又はC2−6のアルキニル基、単環式又は二環式のシクロアルキル基(例えばC1−6のシクロアルキル基)、N、O、及びSから選択されるヘテロ原子を少なくとも1つ含む飽和又は不飽和の単複素環式基又は二複素環式基、単環式又は二環式アリール基、又はN、O、及びSから選択されるヘテロ原子を少なくとも1つ含む単環式又は二環式ヘテロアリール基(例えば、1−3つの窒素原子を含む単環式ヘテロアリール基)から選択され)から選択され、
前記アリール基又はヘテロアリール基は、任意にハロゲン、C1−6のアルキル基に置換され、且つ、R7はC1−6のアルキル基、C2−6のアルケニル基、又はC2−6のアルキニル基、単環式又は二環式アリール基又はヘテロアリール基である。
例えば、環Aは以下の構造の1であり、
1−(1−(2−ヒドロキシアセチル)ピペリジン−3−イル)−3−メチル−8−(6−(1−メチル−1H−ピラゾール−4−イル)ピリジン−3−イル)−1H−イミダゾ[4,5−c]キノリン−2(3H)−オン
1−(1−(1H−1,2,4−トリアゾール−3−カルボニル)ピペリジン−3−イル)−3−メチル−8−(6−(1−メチル−1H−ピラゾール−4−イル)ピリジン−3−イル)−1H−イミダゾ[4,5−c]キノリン−2(3H)−オン
3−メチル−8−(6−(1−メチル−1H−ピラゾール−4−イル)ピリジン−3−イル)−1−(1−(メタンスルホニル)ピペリジン−3−イル)−1H−イミダゾ[4,5−c]キノリン−2(3H)−オン
1−(1−((S)−2−ヒドロキシプロピオニル)ピペリジン−3−イル)−3−メチル−8−(6−(1−メチル−1H−ピラゾール−4−イル)ピリジン−3−イル)−1H−イミダゾ[4,5−c]キノリン−2(3H)−オン
1−(1−((R)−2−ヒドロキシプロピオニル)ピペリジン−3−イル)−3−メチル−8−(6−(1−メチル−1H−ピラゾール−4−イル)ピリジン−3−イル)−1H−イミダゾ[4,5−c]キノリン−2(3H)−オン
3−メチル−8−(6−(1−メチル−1H−ピラゾール−4−イル)ピリジン−3−イル)−1−(1−(メタンスルホニル)ピロリジン−3−イル)−1H−イミダゾ[4,5−c]キノリン−2(3H)−オン
1−(1−(2−ヒドロキシアセチル)ピロリジン−3−イル)−3−メチル−8−(6−(1−メチル−1H−ピラゾール−4−イル)ピリジン−3−イル)−1H−イミダゾ[4,5−c]キノリン−2(3H)−オン
1−(1−(1H−1,2,4−トリアゾール−3−カルボニル)ピロリジン−3−イル)−3−メチル−8−(6−(1−メチル−1H−ピラゾール−4−イル)ピリジン−3−イル)−1H−イミダゾ[4,5−c]キノリン−2(3H)−オン
3−メチル−8−(6−(1−メチル−1H−ピラゾール−4−イル)ピリジン−3−イル)−1−(1−メチルピロリジン−3−イル)−1H−イミダゾ[4,5−c]キノリン−2(3H)−オン
1−(1−エチルピロリジン−3−イル)−3−メチル−8−(6−(1−メチル−1H−ピラゾール−4−イル)ピリジン−3−イル)−1H−イミダゾ[4,5−c]キノリン−2(3H)−オン
1−(1−アセチルピロリジン−3−イル)−3−メチル−8−(6−(1−メチル−1H−ピラゾール−4−イル)ピリジン−3−イル)−1H−イミダゾ[4,5−c]キノリン−2(3H)−オン
1−(1−ベンジルピロリジン−3−イル)−3−メチル−8−(6−(1−メチル−1H−ピラゾール−4−イル)ピリジン−3−イル)−1H−イミダゾ[4,5−c]キノリン−2(3H)−オン
1−(1−((4−クロロフェニル)スルホニル)ピロリジン−3−イル)−3−メチル−8−(6−(1−メチル−1H−ピラゾール−4−イル)ピリジン−3−イル)−1H−イミダゾ[4,5−c]キノリン−2(3H)−オン
3−メチル−8−(6−(1−メチル−1H−ピラゾール−4−イル)ピリジン−3−イル)−1−(1−p−トルエンスルホニルピロリジン−3−イル)−1H−イミダゾ[4,5−c]キノリン−2(3H)−オン
3−(3−メチル−8−(6−(1−メチル−1H−ピラゾール−4−イル)ピリジン−3−イル)−2−オキソ−2,3−ジヒドロ−1H−イミダゾ[4,5−c]キノリン−1−イル)ピロリジン−1−スルホンアミド
3−メチル−8−(6−(1−メチル−1H−ピラゾール−4−イル)ピリジン−3−イル)−1−(1−(2,2,2−トリフルオロアセチル)ピロリジン−3−イル)−1H−イミダゾ[4,5−c]キノリン−2(3H)−オン
1−((1r,4r)−4−ヒドロキシシクロヘキシル)−3−メチル−8−(6−(1−メチル−1H−ピラゾール−4−イル)ピリジン−3−イル)−1H−イミダゾ[4,5−c]キノリン−2(3H)−オン
1−((1s,4s)−4−ヒドロキシシクロヘキシル)−3−メチル−8−(6−(1−メチル−1H−ピラゾール−4−イル)ピリジン−3−イル)−1H−イミダゾ[4,5−c]キノリン−2(3H)−オン
1−((1s,4s)−4−ヒドロキシシクロへキシル)−3−メチル−8−(6−フェニルピリジン−3−イル)−1H−イミダゾ[4,5−c]キノリン−2(3H)−オン
1−((1s,4s)−4−ヒドロキシシクロヘキシル)−8−(6−メトキシ−5−メチルピリジン−3−イル)−3−メチル−1H−イミダゾ[4,5−c]キノリン−2(3H)−オン
1−((1s,4s)−4−ヒドロキシシクロヘキシル)−3−メチル−8−(1−フェニル−1H−ピラゾール−4−イル)−1H−イミダゾ[4,5−c]キノリン−2(3H)−オン
1−((1s,4s)−4−ヒドロキシシクロヘキシル)−3−メチル−8−(6−メチルピリジン−3−イル)−1H−イミダゾ[4,5−c]キノリン−2(3H)−オン
1−((1r,4r)−4−ヒドロキシシクロヘキシル)−3−メチル−8−(1−フェニル−1H−ピラゾール−4−イル)−1H−イミダゾ[4,5−c]キノリン−2(3H)−オン
1−((1r,4r)−4−ヒドロキシシクロヘキシル)−8−(6−メトキシ−5−メチルピリジン−3−イル)−3−メチル−1H−イミダゾ[4,5−c]キノリン−2(3H)−オン
1−((1r,4r)−4−ヒドロキシシクロヘキシル)−3−メチル−8−(6−フェニルピリジン−3−イル)−1H−イミダゾ[4,5−c]キノリン−2(3H)−オン
8−(6−アミノピリジン−3−イル)1−((1s,4s)−4−ヒドロキシシクロヘキシル)−3−メチル−1H−イミダゾ[4,5−c]キノリン−2(3H)−オン
(R)−3−メチル−8−(6−(1−メチル−1H−ピラゾール−4−イル)ピリジン−3−イル)−1−(1−(メタンスルホニル)ピロリジン−3−イル)−1H−イミダゾ[4,5−c]キノリン−2(3H)−オン
(S)−3−メチル−8−(6−(1−メチル−1H−ピラゾール−4−イル)ピリジン−3−イル)−1−(1−(メタンスルホニル)ピロリジン−3−イル)−1H−イミダゾ[4,5−c]キノリン−2(3H)−オン
(S)−1−(1−(エチルスルホニル)ピロリジン−3−イル)−3−メチル−8−(6−(1−メチル−1H−ピラゾール−4−イル)ピリジン−3−イル)−1H−イミダゾ[4,5−c]キノリン−2(3H)−オン
(S)−3−メチル−1−(1−(メタンスルホニル)ピロリジン−3−イル)−8−(6−フェニルピリジン−3−イル)−1H−イミダゾ[4,5−c]キノリン−2(3H)−オン
(R)−3−メチル−8−(6−(1−メチル−1H−ピラゾール−4−イル)ピリジン−3−イル)−1−(1−(メタンスルホニル)ピペリジン−3−イル)−1H−イミダゾ[4,5−c]キノリン−2(3H)−オン
1−(3−ヒドロキシシクロヘキシル)−3−メチル−8−(6−(1−メチル−1H−ピラゾール−4−イル)ピリジン−3−イル)−1H−イミダゾ[4,5−c]キノリン−2(3H)−オン
N−((1s,4s)−4−(3−メチル−8−(6−(1−メチル−1H−ピラゾール−4−イル)ピリジン−3−イル)−2−オキソ−2,3−ジヒドロ−1H−イミダゾ[4,5−c]キノリン−1−イル)シクロヘキシル)アセトアミド
N−((1s,4s)−4−(3−メチル−8−(6−(1−メチル−1H−ピラゾール−4−イル)ピリジン−3−イル)−2−オキソ−2,3−ジヒドロ−1H−イミダゾ[4,5−c]キノリン−1−イル)シクロヘキシル)メタンスルホンアミド
(1s,4s)−4−(3−メチル−8−(6−(1−メチル−1H−ピラゾール−4−イル)ピリジン−3−イル)−2−オキソ−2,3−ジヒドロ−1H−イミダゾ[4,5−c]キノリン−1−イル)シクロヘキサンカルボン酸
3−重水素化メチル−8−(6−(1−メチル−1H−ピラゾール−4−イル)ピリジン−3−イル)−1−(1−(メタンスルホニル)ピペリジン−3−イル)−1H−イミダゾ[4,5−c]キノリン−2(3H)−オン
3−メチル−8−(6−(1−メチル−1H−ピラゾール−4−イル)ピリジン−3−イル)−1−(1−(メタンスルホニル)ピペリジン−3−イル)−1H−イミダゾ[4,5−c][1,5]ナフチリジン−2(3H)−オン
(S)−3−メチル−8−(6−(1−メチル−1H−ピラゾール−4−イル)ピリジン−3−イル)−1−(1−(メタンスルホニル)ピロリジン−3−イル)−1H−イミダゾ[4,5−c][1,5]ナフチリジン−2(3H)−オン
(S)−3−メチル−1−(1−(メタンスルホニル)ピロリジン−3−イル)−8−(6−フェニルピリジン−3−イル)−1H−イミダゾ[4,5−c][1,5]ナフチリジン−2(3H)−オン
2−メチル−2−(4−(3−メチル−8−(6−(1−メチル−1H−ピラゾール−4−イル)ピリジン−3−イル)−2−オキソ−2,3−ジヒドロ−1H−イミダゾ[4,5−c]キノリン−1−イル)フェニル)プロピオンアミド
2−メチル−2−(4−(3−メチル−8−(6−(1−メチル−1H−ピラゾール−4−イル)ピリジン−3−イル)−2−オキソ−2,3−ジヒドロ−1H−イミダゾ[4,5−c]キノリン−1−イル)フェニル)プロピオン酸
1−(3−ヒドロキシシクロペンチル)−3−メチル−8−(6−(1−メチル−1H−ピラゾール−4−イル)ピリジン−3−イル)−1H−イミダゾ[4,5−c]キノリン−2(3H)−オン
(S)−8−(6−(1H−1,2,4−トリアゾール−1−イル)ピリジン−3−イル)−3−メチル−1−(1−(メタンスルホニル)ピロリジン−3−イル)−1H−イミダゾ[4,5−c]キノリン−2(3H)−オン
(S)−8−(6−(1H−ピラゾール−1−イル)ピリジン−3−イル)−3−メチル−1−(1−(メタンスルホニル)ピロリジン−3−イル)−1H−イミダゾ[4,5−c]キノリン−2(3H)−オン
(S)−3−メチル−8−(6−(1−メチル−1H−1,2,3−トリアゾール−4−イル)ピリジン−3−イル)−1−(1−(メタンスルホニル)ピロリジン−3−イル)−1H−イミダゾ[4,5−c]キノリン−2(3H)−オン
(S)−8−(6−(1H−1,2,3−トリアゾール−1−イル)ピリジン−3−イル)−3−メチル−1−(1−(メタンスルホニル)ピロリジン−3−イル)−1H−イミダゾ[4,5−c]キノリン−2(3H)−オン
(S)−3−メチル−8−(6−(1−メチル−1H−ピラゾール−3−イル)ピリジン−3−イル)−1−(1−(メタンスルホニル)ピロリジン−3−イル)−1H−イミダゾ[4,5−c]キノリン−2(3H)−オン
(S)−3−メチル−8−(6−(1−メチル−1H−1,2,4−トリアゾール−3−イル)ピリジン−3−イル)−1−(1−(メタンスルホニル)ピロリジン−3−イル)−1H−イミダゾ[4,5−c]キノリン−2(3H)−オン
(R)−3−メチル−8−(6−(1−メチル−1H−ピラゾール−4−イル)ピリジン−3−イル)−1−(1−(メタンスルホニル)ピペリジン−3−イル)−1H−イミダゾ[4,5−c][1,5]ナフチリジン−2(3H)−オン
(S)−3−メチル−8−(6−(1−メチル−1H−1,2,3−トリアゾール−4−イル)ピリジン−3−イル)−1−(1−(メタンスルホニル)ピロリジン−3−イル)−1H−イミダゾ[4,5−c][1,5]ナフチリジン−2(3H)−オン
1−((1s,4s)−4−ヒドロキシシクロヘキシル)−3−メチル−8−(6−(1−メチル−1H−1,2,3−トリアゾール−4−イル)ピリジン−3−イル)−1H−イミダゾ[4,5−c]キノリン−2(3H)−オン
(R)−1−(1−エチルスルホニル)ピペリジン−3−イル)−3−メチル−8−(6−(1−メチル−1H−ピラゾール−4−イル)ピリジン−3−イル)−1H−イミダゾ[4,5−c]キノリン−2(3H)−オン
(R)−1−(1−シクロプロピルスルホニル)ピペリジン−3−イル)−3−メチル−8−(6−(1−メチル−1H−ピラゾール−4−イル)ピリジン−3−イル)−1H−イミダゾ[4,5−c]キノリン−2(3H)−オン
(R)−3−(3−メチル−8−(6−(1−メチル−1H−ピラゾール−4−イル)ピリジン−3−イル)−2−オキソ−2,3−ジヒドロ−1H−イミダゾ[4,5−c]キノリン−1−イル)ピペリジン−1−スルホンアミド
(R)−N−エチル−3−(3−メチル−8−(6−(1−メチル−1H−ピラゾール−4−イル)ピリジン−3−イル)−2−オキソ−2,3−ジヒドロ−1H−イミダゾ[4,5−c]キノリン−1−イル)ピペリジン−1−ホルムアミド
(R)−3−メチル−8−(6−(1−メチル−1H−ピラゾール−4−イル)ピリジン−3−イル)−1−(1−((トリフルオロメチル)スルホニル)ピペリジン−3−イル)−1H−イミダゾ[4,5−c]キノリン−2(3H)−オン
1−(4−ヒドロキシ−4−メチルシクロヘキシル)−3−メチル−8−(6−(1−メチル−1H−ピラゾール−4−イル)ピリジン−3−イル)−1H−イミダゾ[4,5−c]キノリン−2(3H)−オン
(R)−3−メチル−8−(6−(1−メチル−1H−1,2,3−トリアゾール−4−イル)ピリジン−3−イル)−1−(1−(メタンスルホニル)ピペリジン−3−イル)−1H−イミダゾ[4,5−c]キノリン−2(3H)−オン
3−メチル−8−(6−(1−メチル−1H−ピラゾール−4−イル)ピリジン−3−イル)−1−(1−(メタンスルホニル)ピペリジン−4−イル)−1H−イミダゾ[4,5−c]キノリン−2(3H)−オン
3−メチル−8−(6−(1−メチル−1H−1,2,3−トリアゾール−4−イル)ピリジン−3−イル)−1−(1−(メタンスルホニル)ピペリジン−4−イル)−1H−イミダゾ[4,5−c]キノリン−2(3H)−オン
3−メチル−8−(6−(1−メチル−1H−1,2,3−トリアゾール−4−イル)ピリジン−3−イル)−1−(8−(メタンスルホニル)−8−アザビシクロ[3.2.1]オクタン−3−イル)−1H−イミダゾ[4,5−c]キノリン−2(3H)−オン
3−メチル−8−(6−(1−メチル−1H−ピラゾール−4−イル)ピリジン−3−イル)−1−(8−(メタンスルホニル)−8−アザビシクロ[3.2.1]オクタン−3−イル)−1H−イミダゾ[4,5−c]キノリン−2(3H)−オン
N−(2−(3−メチル−8−(6−(1−メチル−1H−ピラゾール−4−イル)ピリジン−3−イル)−2−オキソ−2,3−ジヒドロ−1H−イミダゾ[4,5−c]キノリン−1−イル)エチル)メタンスルホンアミド
3−メチル−8−(6−(1−メチル−1H−ピラゾール−4−イル)ピリジン−3−イル)−1−(1−(メタンスルホニル)アゼチジン−3−イル)−1H−イミダゾ[4,5−c]キノリン−2(3H)−オン
特に断りのない限り、本明細書にて使用される技術用語が有する意味は、請求項の保護対象が属する技術分野の技術者に一般に理解される意味と同様な意味を有する。特に断りのない限り、本明細書全体に引用される全ての特許、特許出願、公開資料のいずれも引用方式で一体的に本明細書中に組み込まれる。本明細書は用語に対し複数の定義がある場合、本章における定義に準じる。
<合成ルート>
装置:Agilent LCMS1260/MSD6120
カラム:Agilent SB−C18,2.1*50mm,1.8μm,SN:USWEY07289
移動相:A:H20(0.1%FA)90%,B:ACN 10%,0.400mL/min,45.00℃
スケジュール
時間 関数 パラメータ
2.24 溶媒成分変更 溶媒成分 A:0.0% B:100.0%
3.00 溶媒成分変更 溶媒成分 A:0.0% B:100.0%
3.01 流量変更 流量:0.5mL/min
3.01 溶媒成分変更 溶媒成分 A:90.0% B:10.0%
5.00 溶媒成分変更 溶媒成分 A:90.0% B:10.0%
5.01 流量変更 流量:0.4mL/min
5.01 溶媒成分変更 溶媒成分 A:90.0% B:10.0%
装置パラメータ:
イオン化モード :API−ES
極性 :正
衝突誘起解離昇順 :禁止
サイクル時間比率 :50.00%
70gの氷、32gのNaOHを混合し、攪拌しながら15.4mLのニトロメタンを徐々に加え、0℃で1h攪拌する。その後、それを70gの氷と37%のHCl72mLとの混合物に注入しておく。2000mLの1つ口フラスコに50gの2−アミノ−5−ブロモ安息香酸、300mLの水、300mLのアセトンを加え、予備液を加え、室温で反応させ、TLCによりモニターする。反応終了後、溶液を濾過し、吸引乾燥する。黄色固体である中間体1を50.25g得、収率は76%である。
50.25g(0.175mol)の中間体1を500mlの1つ口フラスコに投入し、250mLの無水酢酸を加え、60℃まで昇温し、18.2gの酢酸カリウム(0.23mol)を加える。110℃まで昇温して反応させ、TLCによりモニターする。4h後に、室温まで冷却し、濾過し、酢酸により無色になるまで洗浄し、白色固体である中間体2を26.8g得、収率は56%である。
26.8g(99mmol)の中間体2を500mlの1つ口フラスコに投入し、200mLのオキシ塩化リンを加え、120℃で1h還流し、TLCによりモニターする。反応終了後、それを大量の氷水に投入し、沈殿が析出するまで攪拌する。濾過し、濾過ケーキを氷水により洗浄してジクロロメタンに溶解させる。有機相を塩水により3回洗浄し、無水硫酸マグネシウムにより乾燥し、ロータリエバポレーターで溶媒を蒸発させ、中間体3を16.1g得、収率は53%である。
中間体604:2−(1−メチル−1H−1,2,3−トリアゾール−4−イル)−5−(4,4,5,5−テトラメチル−1,3,2−ジオキサボラン−2−イル)ピリジン
実施例52:(R)−1−(1−エチルスルホニル)ピペリジン−3−イル)−3−メチル−8−(6−(1−メチル−1H−ピラゾール−4−イル)ピリジン−3−イル)−1H−イミダゾ[4,5−c]キノリン−2(3H)−オン
以下、本発明の化合物に対し生物活性検測を行なう。
1.mTORキナーゼ活性試験
化合物によりmTORキナーゼの活性に対する抑制は、インビトロ酵素活性試験により測定される。Invitrogenが提供する検測試薬キットはmTORキナーゼの活性に対する抑制を検測することに用いられる。その試験原理は、mTORキナーゼ、フルオレセインに標識される基質、及びATPを混合し、反応が開始した後、EDTA及びテルビウムに標識される第1抗体を加える。mTORキナーゼの化学反応過程において、抗体は、リン酸化し、且つフルオレセインに標識される基質を認識した後、時間分解蛍光共鳴エネルギー転移(TR−FRET)効果を高める。TR−FRET効果は、受容体であるフルオレセイン信号と供与体であるテルビウム信号との比率により計算する。トレーサーに結合する抗体の量は、反応後のリン酸化の基質の量に比例し、この方式により、キナーゼの活性を検測することができる。この試験において、mTORキナーゼの基質は、緑色蛍光蛋白に接続される4E結合蛋白1(GFP−4EBP1)である。
4−ヒドロキシエチルピペラジンエタンスルホン酸(HEPES、Sigma、Cat# SH3375)、エチレングリコール−ビス−(2−アミノエチルエーテル)四酢酸(EGTA、Sigma、Cat# E3889)、塩化マンガン(MnCl2、Sigma、Cat# M1787)、トゥイーン−20(Tween−20、Amresco)、1,4−ジチオトレイトール(DTT,Merck、CB233155)、アデノシン三リン酸(ATP、sigma、A7699)、哺乳類ラパマイシン標的蛋白(mTOR、Invitrogen、Cat# PV4753)、抗46位のスレオニンのリン酸化の4E結合蛋白1の抗体(Anti−4E binding protein 1 phosphorylated at Thr46−antibody)(LanthaScreen(登録商標) Tb−anti−p4E−BP1 (pThr46) Antibody、Invitrogen、Cat# PV4757)、緑色蛍光蛋白に接続される4E結合蛋白1(GFP−4E−BP1、Invitrogen、Cat# PV4759)、TR−FRET希釈液(TR−FRET Dilution Buffer、Invitrogen、Cat# PV3574)、Proxiプレート、黒色(ProxiPlate、Black、PerkinElmer、検測プレート)、384ウェルプレート(384−well plates、Corning、希釈プレート)、Nunc PPプレート(Nunc PP plate、Corning、希釈プレート)、Envision−2104プレートリーダー(Perkin Elmer)。
1.2.1 1X検測用緩衝貯蔵液
50mM HEPES pH7.5, 1mM EGTA,0.01% Tween−20, 10mM MnCl2,mM DTT。
1.2.2 基質作動溶液
4 mL 2.5×基質(1000つの反応): 3.8mL 1×検測液,191μL GFP−4E−BP1(20.96μM貯蔵液),10μL ATP(10mM)。最終濃度:0.4μM GFP−4E−BP1;10M ATP。
1.2.3 mTOR作動溶液
4mL 2.5×mTOR(1000つの反応):4mL。
1.2.4 1×検測液
7.5μL mTOR(0.4mg/mL 貯蔵液),最終濃度は0.3μg/mLである。
1.2.5検測作動液
10mL 2×検測緩衝液(1000つの反応): 9.6mL TR−FRET 希釈液,11.5μL Tb−anti−p4E−BP1抗体(stock 3.49μM),400μL EDTA(貯蔵液500mM),最終濃度:2nM Tb−anti−p4E−BP1抗体,10mM EDTA。
1.3.1 ジメチルスルホキシド(DMSO)により希釈された濃度が100μMである本発明に係る化合物50μLを38孔の希釈プレートに加える。
1.3.2 ジメチルスルホキシド(DMSO)を用いて1:3の比率で化合物を希釈する(10つの希釈倍率及び1つの零濃度)。
1.3.3 2.5μLの希釈された化合物(表1中の化合物)を、対応の孔(47.5μLの検測液/各孔を含有する)に投入し、数秒振る。
1.3.4 4μLのmTOR作動液を384孔の黒色Proxiプレートに加える。
1.3.5 2μLの希釈された化合物を検測プレートに加える(各濃度は3つの孔を有する)。
1.3.6 室温で15分間インキュベートする。
1.3.7 4μLの基質作動溶液を加える。
1.3.8 最終mTOR反応濃度:0.3μg/mL mTOR,0.4μM GFP−4E−BP1,10μM アデノシン三リン酸(ATP)である。1% ジメチルスルホキシド(DMSO)を用いて化合物を以下の濃度に希釈する:1μM、0.33μM、0.11μM、0.037μM、0.0123μM、0.00411μM、0.00137μM、0.000457μM、0.000152μM、0.000051μM、0μM。
1.3.9 室温で30分間インキュベートする。
1.3.10 10μLの検測液を加え、最終作動濃度:Tb−anti−p4E−BP1 抗体 2nM, EDTA 10mM。
1.3.11 室温で30分間インキュベートする。
1.3.12 EnvisionプレートリーダーによりTR−FRETの読み取り値を検測する。励起光は340nmであり、発光1は495nmであり、発光2は520nmである。比率=520nm/495nmはTR−FRET値である。
1.3.13 データー分析及び50%抑制率の計算(IC50)
非線形回帰式により50%抑制率を計算する。
Y=底部+(頂部−底部)/(1+10^((LogIC50−X)*HillSlope))、Xは化合物の濃度(10を底にした対数)であり、YはTR−FRET値(520nmが495nmに対する比率)であり、頂部及び底部は同一のピーク値をYとし(Plateaus in same units as Y)、50%抑制率(logIC50)は同一の対数値をXとする(same log units as X)。表1はmTOR酵素の抑制活性を示す。
ATPは生細胞代謝活動において必然に発生するものであり、その含有量と生細胞数量とは、直線関係がある。CTG化学発光細胞活力検測実験は、この原理を基づき、培養細胞における生存細胞数を検測する通用方法である。CellTiter−Glo(CTG)試薬を加えた後、細胞分解を誘導し、且つウェルプレートにおけるATP数量と比例関係が成立する化学発光信号を生成することができ、これによって、化学発光の読み取り値によりウェルプレートにおける細胞増殖の活力を評価する。
2.1.1 実験材料
試験対象化合物、細胞基礎培地、RPMI Medium 1640(Invitrogen、Cat#11875−093),ウシ胎児血清(FBS):Hyclone FETAL BOVINE SERUM DEFINED(Invitrogen、Cat#SH30070.03),抗生物質:Penicilin Streptomycin(Invitrogen、Cat#15140−122)、リン酸塩緩衝液(Corning Cellgro、Cat#R21−040−CV)、細胞消化液:0.25%Trypsin−EDTA(Invitrogen、Cat#25200−056)、CTG検測試薬キット:Promega、Cat#G7571、96孔のブラック平底プレート:NUNC、Cat#165305、T25培養瓶:NUNC、Cat#156367、T75培養瓶:NUNC、Cat#156439。
二酸化炭素インキュベーターはSANYO−MCO−20AICであり、生物安全キャビネットはBSC−1360−LIIA2であり、卓上高速冷却遠心機はSorvallST 16Rであり、マイクロウェルプレート快速発振器はQB−9001であり、M3プレートリーダーはSpectraMax M3であり、顕微鏡はOLYMPUS−CKX41/CKX31である。
細胞成長培地の調製はRPMI Medium 1640+10%FBS+抗生物質であり、その他、トリプシン消化溶液、リン酸塩緩衝液(PBS)、DMSO,CTG検測試薬キットを準備する。
2.4.1 細胞蘇生
液体窒素容器からクライオチューブを取り出し、直接に37℃の水浴に浸入し、それを早速に融解するために適宜揺動し、37℃水浴からクライオチューブを取り出し、生物安全キャビネットに移動し、蓋を開け、吸引チューブにより細胞懸濁液を吸出し、遠心管に加え、10倍以上の培養液を滴下し、均一に混合し、1000rpm、5min遠心し、上澄み液を廃棄し、細胞成長培地を加え、細胞を再度懸濁させ、全部の細胞懸濁液をT25培養瓶に接種し、37℃でインキュベーターに静置培養し、翌日培養液を1回交換し、培養し続ける。
細胞が対数成長期に成長し、コンフルエンスが80%−90%になる際に、細胞を取り出し、生物安全キャビネットに入り、旧培養液を廃棄し、PBSで細胞を1−2回リンスし、0.25%のTrypsin−EDTA細胞消化液を適量取り、培養瓶に加え、37℃で二酸化炭素インキュベーターに2−5min放置し、10%のFBSを含む細胞成長培地を適量加え、消化を停止し、軽くパットして、遠心管に転移し、1000rpm、5min遠心し、細胞を細胞懸濁液にした後、継代及び実験に用いられる。
2.4.3.1 細胞懸濁液の製造は、以下のとおりである。
細胞が対数成長期に成長し、コンフルエンスが80%−90%になる際に、細胞を取り出し、生物安全キャビネットに入り、旧培養液を廃棄し、PBSで細胞を1−2回リンスし、0.25%のTrypsin−EDTA細胞消化液を適量取り、培養瓶に加え、37度で二酸化炭素インキュベーターに2−5min放置し、10%のFBSを含む細胞成長培地を適量加え、消化を停止し、軽くパットして、遠心管に転移し、1000rpm、5min遠心し、計数し、細胞懸濁液の濃度を適合の濃度に調節する(細胞活力が90%より大きくする)。
2.4.3.2 調節された最終濃度の細胞懸濁液を96ウェルプレートに加え、各孔が100uLである。
2.4.3.3 37℃で、5%のCO2インキュベーターに24h培養する。
2.4.4.1 試験化合物貯留液の調製
試験化合物粉末をDMSOに溶解させ、濃度が10mMである。
2.4.4.2 試験化合物段階希釈液の調製
先ず、1uLの試験化合物貯留液を、10%のFBSを含む細胞成長培地499uLに加え、この時、試験化合物の最高濃度が20uMであり、DMSO濃度が0.2%であり、更に0.2%のDMSOを含む細胞成長培地を用いて、20uMの試験化合物を3倍で9つの濃度希釈し、合わせて10つの濃度グラジエントである。
2.4.4.3 試験化合物の添加
調製された段階試験化合物希釈液を細胞培養板に加え、各孔は100uLであり、この時、試験化合物の最高濃度が10uMであり、DMSOの最終濃度が0.1%であり、各濃度グラジエントは2つの孔を用い、ブランクコントロール孔(0.1%のDMSOを含む細胞成長培地だけを加え、細胞を加えない)及び陰性コントロール孔(細胞及び0.1%のDMSOを含む細胞成長培地)を設置する。
2.4.4.4 試験化合物を加えた後、37℃で5%のCO2インキュベータに1つの増倍時間作用する。
2.4.5.1 検測
細胞培養板を取り出し、各孔から100uLの培養液を取り出し廃棄し、調製されたCTG基質を培養板に加え、各孔が50uLである。加えた後、直ぐにマイクロウェルプレート快速発振器に2min発振し、その後、遮光条件下10min静置し、発光信号をバランスし、M3プレートリーダーで読み取る。
2.4.5.2 データー分析
GraphPad作図ソフトによりデーター統計分析を行う。
PI3K alpha−ADP Glo Assayを採用する。PI3K酵素活性測定において、Promegaに提供された検測試薬キット(Promega、カタログ番号:V9101)は、化合物がPI3K酵素活性に対する抑制作用の検測に用いられる。全体の酵素学的反応において、生成したアデノシン二リン酸(ADP)は定量される。得られた数値は、PI3Kの活性の計算に用いられることができる(表1)。
PIK3CA/PIK3R1はInvitrogen製(カタログ番号:PV4788)であり、キナーゼ希釈液IIIを用いて活性キナーゼを希釈し、1:4の比率(5X希釈)で、ウシ血清アルブミン(BSA)と混合し、最終BSAの濃度は50ng/mlであり、キナーゼ検測液Iの成分は、25mM MOPS、pH7.2、12.5mM β−グリセロリン酸塩、25mM 塩化マグネシウム、5mM EGTA、2mM EDTAである。使用前に、0.25mMのDTTをキナーゼ検測液Iに加える。250μMのアデノシン三リン酸(ATP)検測液は、0.55mgのATPを4mlのキナーゼ検測液Iに加え、各管200μlに分注し、−20℃で貯蔵する。基質は、ホスファチジルイノシトール(4,5)ビスリン酸[Phosphatidylinositol (4,5)bis−phosphate]であり、この基質をキナーゼ検測液Iにより125μMまで希釈する。最終濃度は:10μM PIP2, 10μM ATP, 1%のDMSO, 0.0005−10μM 化合物である。
3.2.1 ジメチルスルホキシド(DMSO)で希釈された濃度が100μMである化合物50μLを384孔の希釈プレートに加える。ジメチルスルホキシド(DMSO)により1:3の比率で化合物を希釈する(10つの希釈倍率および1つの零濃度)。
3.2.2 5μLの希釈された化合物を対応の384孔の黒色Proxiプレート(47.5μLの検測液/各孔を含有する)に転入し、数秒振る。
3.2.3 2μLの2.5xPI3K作動液を384孔の黒色Proxiプレートに加える。
3.2.4 2μLの希釈された化合物を検測プレートに加える(各濃度は3つの孔を有する)。
3.2.5 室温で2時間インキュベートする。
3.2.6 5μLのADP Glo試薬を加える。
3.2.7 室温で40分間インキュベートする。
3.2.8 10μLのキナーゼ検測試薬を加える。
3.2.9 室温で40分間インキュベートする。
3.2.10 Envisionプレートリーダーにより検測する。
Prism5ソフトでIC50を計算し、その結果は、本発明に係る化合物がmTORプロテアーゼの活性に対して抑制作用を有することを表明する。化合物のmTORプロテアーゼの活性抑制範囲は、0.5−数百ナノモルであり、表1に示す。測定されたPI3K酵素活性の抑制を表2に示す。測定された腫瘍細胞系の抑制データーを表1に示す。これらのデーターは、本発明に係る化合物が、mTOR、PI3Kプロテアーゼの活性を抑制し、及び抗腫瘍活性を有することを表明する。
4.1 動物試験
ネズミに試験対象化合物を経口投与し、それがネズミ血漿における生物利用度及び薬物動態学的特性を測定する。
4.2 試験方法
投与経路:胃内投与(PO)、投与用量は10mg/kgであり、投与最終濃度は1mg/mLであり、投与体積は10mL/kgである。
4.3 全血試料収集
動物から採血し、毎回約300μLである。投与前に、1回採血し、投与後0.25時間、0.5時間、1時間、2時間、4時間、6時間、8時間、24時間採血する。収集した血液試料を、4℃、2000rpmで5min遠心し、得られた血漿をポリエチレン微量遠心管に転移し、その後、−80℃の冷蔵庫に放置する。
4.4 生物試料分析方法
LC/MS/MS 生物試料分析方法。
4.5 試験結果
化合物が動物体内の最高濃度、半減期及び6時間の化合物の血液における濃度及びAUCを測定する(表3)。
Claims (7)
- 式Iで示す化合物、又はその薬学的に許容される塩、立体異性体、若しくは同位体標識物質:
[ここで、
環Aは、ピラゾール、フェニル、及びトリアゾールから選択され、
環Bは、ピラゾール及びピリジルから選択され、
環Cは、シクロペンチル基、シクロヘキシル基、アゼチジニル、ピペリジニル、及びピロリジニルから選択され、
R1は、
フェニル基によって置換されているC1−3のアルキル基、
及び、
R6CO−、R6SO2−、又はR 6 SO−(ここで、R6は、−NH2 及び−NHR 7 から選択され、R 7 は、メチル、エチル、トリアゾール、及びシクロプロピルから選択される)
から選択され、
R2はH、メチル、エチル、n−プロピル、及びイソプロピルから選択され、
R3はH、メチル、エチル、n−プロピル、及びイソプロピルから選択され、
R4は環Aに結合している少なくとも1つの基であり、各R4はH、メチル、エチル、n−プロピル、及びイソプロピルから独立に選択され、
XはCHである]。 - R 1 は、フェニル基によって置換されているC 1−3 のアルキル基から選択され、
R2は、H及びメチルから選択され、
R3は、H及びメチルから選択され、
R4は、H及びメチルから選択されること、
を特徴とする請求項1に記載の化合物、又はその薬学的に許容される塩、立体異性体、若しくは同位体標識物質。 - 以下の化合物群から選択される化合物、又はその薬学的に許容される塩、立体異性体、若しくは同位体標識物質:
1−(1−(2−ヒドロキシアセチル)ピペリジン−3−イル)−3−メチル−8−(6−(1−メチル−1H−ピラゾール−4−イル)ピリジン−3−イル)−1H−イミダゾ[4,5−c]キノリン−2(3H)−オン、
1−(1−(1H−1,2,4−トリアゾール−3−カルボニル)ピペリジン−3−イル)−3−メチル−8−(6−(1−メチル−1H−ピラゾール−4−イル)ピリジン−3−イル)−1H−イミダゾ[4,5−c]キノリン−2(3H)−オン、
3−メチル−8−(6−(1−メチル−1H−ピラゾール−4−イル)ピリジン−3−イル)−1−(1−(メタンスルホニル)ピペリジン−3−イル)−1H−イミダゾ[4,5−c]キノリン−2(3H)−オン、
1−(1−((S)−2−ヒドロキシプロピオニル)ピペリジン−3−イル)−3−メチル−8−(6−(1−メチル−1H−ピラゾール−4−イル)ピリジン−3−イル)−1H−イミダゾ[4,5−c]キノリン−2(3H)−オン、
1−(1−((R)−2−ヒドロキシプロピオニル)ピペリジン−3−イル)−3−メチル−8−(6−(1−メチル−1H−ピラゾール−4−イル)ピリジン−3−イル)−1H−イミダゾ[4,5−c]キノリン−2(3H)−オン、
3−メチル−8−(6−(1−メチル−1H−ピラゾール−4−イル)ピリジン−3−イル)−1−(1−(メタンスルホニル)ピロリジン−3−イル)−1H−イミダゾ[4,5−c]キノリン−2(3H)−オン、
1−(1−(2−ヒドロキシアセチル)ピロリジン−3−イル)−3−メチル−8−(6−(1−メチル−1H−ピラゾール−4−イル)ピリジン−3−イル)−1H−イミダゾ[4,5−c]キノリン−2(3H)−オン、
1−(1−(1H−1,2,4−トリアゾール−3−カルボニル)ピロリジン−3−イル)−3−メチル−8−(6−(1−メチル−1H−ピラゾール−4−イル)ピリジン−3−イル)−1H−イミダゾ[4,5−c]キノリン−2(3H)−オン、
3−メチル−8−(6−(1−メチル−1H−ピラゾール−4−イル)ピリジン−3−イル)−1−(1−メチルピロリジン−3−イル)−1H−イミダゾ[4,5−c]キノリン−2(3H)−オン、
1−(1−エチルピロリジン−3−イル)−3−メチル−8−(6−(1−メチル−1H−ピラゾール−4−イル)ピリジン−3−イル)−1H−イミダゾ[4,5−c]キノリン−2(3H)−オン、
1−(1−アセチルピロリジン−3−イル)−3−メチル−8−(6−(1−メチル−1H−ピラゾール−4−イル)ピリジン−3−イル)−1H−イミダゾ[4,5−c]キノリン−2(3H)−オン、
1−(1−ベンジルピロリジン−3−イル)−3−メチル−8−(6−(1−メチル−1H−ピラゾール−4−イル)ピリジン−3−イル)−1H−イミダゾ[4,5−c]キノリン−2(3H)−オン、
1−(1−((4−クロロフェニル)スルホニル)ピロリジン−3−イル)−3−メチル−8−(6−(1−メチル−1H−ピラゾール−4−イル)ピリジン−3−イル)−1H−イミダゾ[4,5−c]キノリン−2(3H)−オン、
3−メチル−8−(6−(1−メチル−1H−ピラゾール−4−イル)ピリジン−3−イル)−1−(1−p−トルエンスルホニルピロリジン−3−イル)−1H−イミダゾ[4,5−c]キノリン−2(3H)−オン、
3−(3−メチル−8−(6−(1−メチル−1H−ピラゾール−4−イル)ピリジン−3−イル)−2−オキソ−2,3−ジヒドロ−1H−イミダゾ[4,5−c]キノリン−1−イル)ピロリジン−1−スルホンアミド、
3−メチル−8−(6−(1−メチル−1H−ピラゾール−4−イル)ピリジン−3−イル)−1−(1−(2,2,2−トリフルオロアセチル)ピロリジン−3−イル)−1H−イミダゾ[4,5−c]キノリン−2(3H)−オン、
1−((1r,4r)−4−ヒドロキシシクロヘキシル)−3−メチル−8−(6−(1−メチル−1H−ピラゾール−4−イル)ピリジン−3−イル)−1H−イミダゾ[4,5−c]キノリン−2(3H)−オン、
1−((1s,4s)−4−ヒドロキシシクロヘキシル)−3−メチル−8−(6−(1−メチル−1H−ピラゾール−4−イル)ピリジン−3−イル)−1H−イミダゾ[4,5−c]キノリン−2(3H)−オン、
1−((1s,4s)−4−ヒドロキシシクロへキシル)−3−メチル−8−(6−フェニルピリジン−3−イル)−1H−イミダゾ[4,5−c]キノリン−2(3H)−オン、
1−((1s,4s)−4−ヒドロキシシクロヘキシル)−3−メチル−8−(1−フェニル−1H−ピラゾール−4−イル)−1H−イミダゾ[4,5−c]キノリン−2(3H)−オン、
1−((1r,4r)−4−ヒドロキシシクロヘキシル)−3−メチル−8−(1−フェニル−1H−ピラゾール−4−イル)−1H−イミダゾ[4,5−c]キノリン−2(3H)−オン、
1−((1r,4r)−4−ヒドロキシシクロヘキシル)−3−メチル−8−(6−フェニルピリジン−3−イル)−1H−イミダゾ[4,5−c]キノリン−2(3H)−オン、
(R)−3−メチル−8−(6−(1−メチル−1H−ピラゾール−4−イル)ピリジン−3−イル)−1−(1−(メタンスルホニル)ピロリジン−3−イル)−1H−イミダゾ[4,5−c]キノリン−2(3H)−オン、
(S)−3−メチル−8−(6−(1−メチル−1H−ピラゾール−4−イル)ピリジン−3−イル)−1−(1−(メタンスルホニル)ピロリジン−3−イル)−1H−イミダゾ[4,5−c]キノリン−2(3H)−オン、
(S)−1−(1−(エチルスルホニル)ピロリジン−3−イル)−3−メチル−8−(6−(1−メチル−1H−ピラゾール−4−イル)ピリジン−3−イル)−1H−イミダゾ[4,5−c]キノリン−2(3H)−オン、
(S)−3−メチル−1−(1−(メタンスルホニル)ピロリジン−3−イル)−8−(6−フェニルピリジン−3−イル)−1H−イミダゾ[4,5−c]キノリン−2(3H)−オン、
(R)−3−メチル−8−(6−(1−メチル−1H−ピラゾール−4−イル)ピリジン−3−イル)−1−(1−(メタンスルホニル)ピペリジン−3−イル)−1H−イミダゾ[4,5−c]キノリン−2(3H)−オン、
1−(3−ヒドロキシシクロヘキシル)−3−メチル−8−(6−(1−メチル−1H−ピラゾール−4−イル)ピリジン−3−イル)−1H−イミダゾ[4,5−c]キノリン−2(3H)−オン、
N−((1s,4s)−4−(3−メチル−8−(6−(1−メチル−1H−ピラゾール−4−イル)ピリジン−3−イル)−2−オキソ−2,3−ジヒドロ−1H−イミダゾ[4,5−c]キノリン−1−イル)シクロヘキシル)アセトアミド、
N−((1s,4s)−4−(3−メチル−8−(6−(1−メチル−1H−ピラゾール−4−イル)ピリジン−3−イル)−2−オキソ−2,3−ジヒドロ−1H−イミダゾ[4,5−c]キノリン−1−イル)シクロヘキシル)メタンスルホンアミド、
(1s,4s)−4−(3−メチル−8−(6−(1−メチル−1H−ピラゾール−4−イル)ピリジン−3−イル)−2−オキソ−2,3−ジヒドロ−1H−イミダゾ[4,5−c]キノリン−1−イル)シクロヘキサンカルボン酸、
3−重水素化メチル−8−(6−(1−メチル−1H−ピラゾール−4−イル)ピリジン−3−イル)−1−(1−(メタンスルホニル)ピペリジン−3−イル)−1H−イミダゾ[4,5−c]キノリン−2(3H)−オン、
2−メチル−2−(4−(3−メチル−8−(6−(1−メチル−1H−ピラゾール−4−イル)ピリジン−3−イル)−2−オキソ−2,3−ジヒドロ−1H−イミダゾ[4,5−c]キノリン−1−イル)フェニル)プロピオンアミド、
2−メチル−2−(4−(3−メチル−8−(6−(1−メチル−1H−ピラゾール−4−イル)ピリジン−3−イル)−2−オキソ−2,3−ジヒドロ−1H−イミダゾ[4,5−c]キノリン−1−イル)フェニル)プロピオン酸、
1−(3−ヒドロキシシクロペンチル)−3−メチル−8−(6−(1−メチル−1H−ピラゾール−4−イル)ピリジン−3−イル)−1H−イミダゾ[4,5−c]キノリン−2(3H)−オン、
(S)−8−(6−(1H−1,2,4−トリアゾール−1−イル)ピリジン−3−イル)−3−メチル−1−(1−(メタンスルホニル)ピロリジン−3−イル)−1H−イミダゾ[4,5−c]キノリン−2(3H)−オン、
(S)−8−(6−(1H−ピラゾール−1−イル)ピリジン−3−イル)−3−メチル−1−(1−(メタンスルホニル)ピロリジン−3−イル)−1H−イミダゾ[4,5−c]キノリン−2(3H)−オン、
(S)−3−メチル−8−(6−(1−メチル−1H−1,2,3−トリアゾール−4−イル)ピリジン−3−イル)−1−(1−(メタンスルホニル)ピロリジン−3−イル)−1H−イミダゾ[4,5−c]キノリン−2(3H)−オン、
(S)−8−(6−(1H−1,2,3−トリアゾール−1−イル)ピリジン−3−イル)−3−メチル−1−(1−(メタンスルホニル)ピロリジン−3−イル)−1H−イミダゾ[4,5−c]キノリン−2(3H)−オン、
(S)−3−メチル−8−(6−(1−メチル−1H−ピラゾール−3−イル)ピリジン−3−イル)−1−(1−(メタンスルホニル)ピロリジン−3−イル)−1H−イミダゾ[4,5−c]キノリン−2(3H)−オン、
(S)−3−メチル−8−(6−(1−メチル−1H−1,2,4−トリアゾール−3−イル)ピリジン−3−イル)−1−(1−(メタンスルホニル)ピロリジン−3−イル)−1H−イミダゾ[4,5−c]キノリン−2(3H)−オン、
1−((1s,4s)−4−ヒドロキシシクロヘキシル)−3−メチル−8−(6−(1−メチル−1H−1,2,3−トリアゾール−4−イル)ピリジン−3−イル)−1H−イミダゾ[4,5−c]キノリン−2(3H)−オン、
(R)−1−(1−エチルスルホニル)ピペリジン−3−イル)−3−メチル−8−(6−(1−メチル−1H−ピラゾール−4−イル)ピリジン−3−イル)−1H−イミダゾ[4,5−c]キノリン−2(3H)−オン、
(R)−1−(1−シクロプロピルスルホニル)ピペリジン−3−イル)−3−メチル−8−(6−(1−メチル−1H−ピラゾール−4−イル)ピリジン−3−イル)−1H−イミダゾ[4,5−c]キノリン−2(3H)−オン、
(R)−3−(3−メチル−8−(6−(1−メチル−1H−ピラゾール−4−イル)ピリジン−3−イル)−2−オキソ−2,3−ジヒドロ−1H−イミダゾ[4,5−c]キノリン−1−イル)ピペリジン−1−スルホンアミド、
(R)−N−エチル−3−(3−メチル−8−(6−(1−メチル−1H−ピラゾール−4−イル)ピリジン−3−イル)−2−オキソ−2,3−ジヒドロ−1H−イミダゾ[4,5−c]キノリン−1−イル)ピペリジン−1−ホルムアミド、
(R)−3−メチル−8−(6−(1−メチル−1H−ピラゾール−4−イル)ピリジン−3−イル)−1−(1−((トリフルオロメチル)スルホニル)ピペリジン−3−イル)−1H−イミダゾ[4,5−c]キノリン−2(3H)−オン、
1−(4−ヒドロキシ−4−メチルシクロヘキシル)−3−メチル−8−(6−(1−メチル−1H−ピラゾール−4−イル)ピリジン−3−イル)−1H−イミダゾ[4,5−c]キノリン−2(3H)−オン、
(R)−3−メチル−8−(6−(1−メチル−1H−1,2,3−トリアゾール−4−イル)ピリジン−3−イル)−1−(1−(メタンスルホニル)ピペリジン−3−イル)−1H−イミダゾ[4,5−c]キノリン−2(3H)−オン、
3−メチル−8−(6−(1−メチル−1H−ピラゾール−4−イル)ピリジン−3−イル)−1−(1−(メタンスルホニル)ピペリジン−4−イル)−1H−イミダゾ[4,5−c]キノリン−2(3H)−オン、
3−メチル−8−(6−(1−メチル−1H−1,2,3−トリアゾール−4−イル)ピリジン−3−イル)−1−(1−(メタンスルホニル)ピペリジン−4−イル)−1H−イミダゾ[4,5−c]キノリン−2(3H)−オン、
3−メチル−8−(6−(1−メチル−1H−1,2,3−トリアゾール−4−イル)ピリジン−3−イル)−1−(8−(メタンスルホニル)−8−アザビシクロ[3.2.1]オクタン−3−イル)−1H−イミダゾ[4,5−c]キノリン−2(3H)−オン、
3−メチル−8−(6−(1−メチル−1H−ピラゾール−4−イル)ピリジン−3−イル)−1−(8−(メタンスルホニル)−8−アザビシクロ[3.2.1]オクタン−3−イル)−1H−イミダゾ[4,5−c]キノリン−2(3H)−オン、
N−(2−(3−メチル−8−(6−(1−メチル−1H−ピラゾール−4−イル)ピリジン−3−イル)−2−オキソ−2,3−ジヒドロ−1H−イミダゾ[4,5−c]キノリン−1−イル)エチル)メタンスルホンアミド、及び
3−メチル−8−(6−(1−メチル−1H−ピラゾール−4−イル)ピリジン−3−イル)−1−(1−(メタンスルホニル)アゼチジン−3−イル)−1H−イミダゾ[4,5−c]キノリン−2(3H)−オン。 - 請求項1〜請求項3の何れか1項に記載の化合物、又はその薬学的に許容される塩、立体異性体、若しくは同位体標識物質と、
その薬学的に許容される担体と、
を含む医薬組成物。 - mTOR及びPI3Kキナーゼの1種又は2種を抑制する薬物の製造における、請求項1〜請求項3の何れか1項に記載の化合物、又はその薬学的に許容される塩、立体異性体、若しくは同位体標識物質の使用。
- 癌、代謝性疾患及び心血管疾患からなる群より選択される少なくとも1種の疾患を治療又は予防する薬物の製造における、請求項1〜請求項3の何れか1項に記載の化合物、又はその薬学的に許容される塩、立体異性体、若しくは同位体標識物質の使用。
- 前記代謝性疾患は糖尿病若しくは肥満症である、請求項6に記載の化合物、又はその薬学的に許容される塩、立体異性体、若しくは同位体標識物質の使用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310589080 | 2013-11-20 | ||
CN201310589080.4 | 2013-11-20 | ||
PCT/CN2014/091138 WO2015074516A1 (zh) | 2013-11-20 | 2014-11-14 | 咪唑酮类衍生物、其药物组合物和用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2016537393A JP2016537393A (ja) | 2016-12-01 |
JP6290412B2 true JP6290412B2 (ja) | 2018-03-07 |
Family
ID=52894558
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016533613A Active JP6290412B2 (ja) | 2013-11-20 | 2014-11-14 | イミダゾロン系誘導体、その医薬組成物及び用途 |
Country Status (8)
Country | Link |
---|---|
US (1) | US10047084B2 (ja) |
EP (1) | EP3072893B1 (ja) |
JP (1) | JP6290412B2 (ja) |
CN (1) | CN104447740B (ja) |
AU (1) | AU2014352463B2 (ja) |
CA (1) | CA2931147C (ja) |
HK (1) | HK1205107A1 (ja) |
WO (1) | WO2015074516A1 (ja) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015074516A1 (zh) | 2013-11-20 | 2015-05-28 | 北京富龙康泰生物技术有限公司 | 咪唑酮类衍生物、其药物组合物和用途 |
CN106995441B (zh) * | 2016-01-26 | 2019-05-21 | 北京富龙康泰生物技术有限公司 | 咪唑酮类化合物的晶型、其制备方法、药物组合物和用途 |
WO2017128042A1 (zh) | 2016-01-26 | 2017-08-03 | 北京富龙康泰生物技术有限公司 | 咪唑酮类化合物的晶型、其制备方法、药物组合物和用途 |
CN106432182B (zh) * | 2016-09-06 | 2019-04-30 | 铜仁学院 | 特地唑胺中间体的合成方法 |
CA3093189A1 (en) | 2018-03-07 | 2019-09-12 | Bayer Aktiengesellschaft | Identification and use of erk5 inhibitors |
JP2023542606A (ja) | 2020-09-21 | 2023-10-11 | ウェイ ジョン | 血液脳関門透過能力を有する置換1-(3,3-ジフルオロピペリジン-4-イル)-イミダゾ[4,5-c]キノリン-2-オン化合物 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010519309A (ja) * | 2007-02-20 | 2010-06-03 | ノバルティス アーゲー | 脂質キナーゼおよびmTORのデュアル阻害剤としてのイミダゾキノリン |
JP5591809B2 (ja) * | 2008-09-30 | 2014-09-17 | ファイザー・インク | イミダゾ[1,5]ナフチリジン化合物、その医薬への使用、および組成物 |
CN102574845B (zh) * | 2009-06-04 | 2015-09-02 | 诺华股份有限公司 | 1H-咪唑并[4,5-c]喹啉酮衍生物 |
AU2010292198A1 (en) * | 2009-09-09 | 2012-04-05 | Celgene Avilomics Research, Inc. | PI3 kinase inhibitors and uses thereof |
CN102372711B (zh) * | 2010-08-18 | 2014-09-17 | 山东轩竹医药科技有限公司 | 咪唑并喹啉类PI3K和mTOR双重抑制剂 |
CN102399218A (zh) * | 2010-09-16 | 2012-04-04 | 和记黄埔医药(上海)有限公司 | 一类并合三杂环及其作为pi3k抑制剂的用途 |
AR084731A1 (es) | 2010-12-06 | 2013-06-05 | Piramal Life Sciences Ltd | Derivados de imidazoquinolina sustituidos |
CN103833752A (zh) * | 2012-11-20 | 2014-06-04 | 北京富龙康泰生物技术有限公司 | 咪唑酮并喹啉类衍生物、其药物组合物和用途 |
WO2015074516A1 (zh) | 2013-11-20 | 2015-05-28 | 北京富龙康泰生物技术有限公司 | 咪唑酮类衍生物、其药物组合物和用途 |
-
2014
- 2014-11-14 WO PCT/CN2014/091138 patent/WO2015074516A1/zh active Application Filing
- 2014-11-14 CN CN201410647871.2A patent/CN104447740B/zh active Active
- 2014-11-14 US US15/037,466 patent/US10047084B2/en active Active
- 2014-11-14 EP EP14863847.1A patent/EP3072893B1/en active Active
- 2014-11-14 CA CA2931147A patent/CA2931147C/en active Active
- 2014-11-14 AU AU2014352463A patent/AU2014352463B2/en active Active
- 2014-11-14 JP JP2016533613A patent/JP6290412B2/ja active Active
-
2015
- 2015-06-09 HK HK15105457.8A patent/HK1205107A1/xx unknown
Also Published As
Publication number | Publication date |
---|---|
EP3072893B1 (en) | 2020-03-18 |
AU2014352463B2 (en) | 2017-05-11 |
AU2014352463A1 (en) | 2016-06-02 |
JP2016537393A (ja) | 2016-12-01 |
US10047084B2 (en) | 2018-08-14 |
EP3072893A4 (en) | 2017-06-21 |
WO2015074516A1 (zh) | 2015-05-28 |
HK1205107A1 (en) | 2015-12-11 |
CA2931147A1 (en) | 2015-05-28 |
CN104447740B (zh) | 2017-02-22 |
CA2931147C (en) | 2018-05-29 |
US20160304510A1 (en) | 2016-10-20 |
CN104447740A (zh) | 2015-03-25 |
EP3072893A1 (en) | 2016-09-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN112225724B (zh) | 苯并咪唑类化合物激酶抑制剂及其制备方法和应用 | |
KR102587758B1 (ko) | 시클린-의존성 키나제 7 (cdk7)의 억제제 | |
US11685746B2 (en) | Heteroaryl compounds for treating Huntington's disease | |
RU2666146C2 (ru) | Соединения и способы модулирования киназы и показания к их применению | |
JP6133291B2 (ja) | ピラゾロ[3,4−c]ピリジン化合物と使用方法 | |
JP6290412B2 (ja) | イミダゾロン系誘導体、その医薬組成物及び用途 | |
AU2014324595B2 (en) | Substituted nicotinimide inhibitors of BTK and their preparation and use in the treatment of cancer, inflammation and autoimmune disease | |
TW202110843A (zh) | 含氮雜環類衍生物調節劑、其製備方法和應用 | |
JP2018150358A (ja) | Tank結合キナーゼインヒビター化合物 | |
AU2016239270A1 (en) | Imidazolonyl quinolines and use thereof as ATM kinase inhibitors | |
US20220259201A1 (en) | Inhibitor containing bicyclic derivative, preparation method therefor and use thereof | |
CN104411706B (zh) | 咪唑酮类衍生物、其药物组合物和用途 | |
TWI580679B (zh) | 雜芳基並嘧啶類衍生物、其製備方法和用途 | |
KR20130036201A (ko) | 헤타릴아미노나프티리딘 | |
CN116655602A (zh) | PI3Kα变构抑制剂 | |
CN105985354B (zh) | 嘧啶衍生物、细胞毒性剂、药物组合物及其应用 | |
WO2023051302A1 (zh) | 具有细胞周期蛋白依赖性激酶抑制活性的杂环化合物及其制备方法和医药用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20160519 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20170413 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170606 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170830 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20171003 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20171227 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20180116 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20180207 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6290412 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |